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2Abstract
 The orphan nuclear receptors REV-ERBα and REV-ERBβ (REV-ERBs) are crucial in 
the regulation of inflammatory-related gene transcription in astroglioma cells, but their 
role in nociceptive transduction has yet to be elaborated. Spinal dorsal horn 
astrocytes contribute to the maintenance of chronic pain. Treatment of cultured spinal 
astrocytes with specific REV-ERBs agonists SR9009 or GSK4112 significantly 
prevented lipopolysaccharide (LPS)-induced mRNA upregulation of pronociceptive 
molecules interleukin-1β (IL-1β) mRNA, interleukin-6 (IL-6) mRNA and matrix 
metalloprotease-9 (MMP-9) mRNA, but not CCL2 mRNA expression. Treatment with 
SR9009 also blocked tumor necrosis factor-induced IL-1β mRNA, IL-6 mRNA and 
MMP-9 mRNA. In addition, treatment with SR9009 significantly blocked LPS-induced 
upregulation of IL-1β protein, IL-6 protein and MMP-9 activity. The inhibitory effects of 
SR9009 on LPS-induced expression of pronociceptive molecules were blocked by 
knockdown of REV-ERBs expression with short interference RNA, confirming that 
SR9009 exerts its effect through REV-ERBs. Intrathecal LPS treatment in male mice 
induces hind paw mechanical hypersensitivity, and upregulation of IL-1β mRNA, IL-6 
mRNA and glial fibrillary acidic protein (GFAP) expression in spinal dorsal horn. 
Intrathecal pretreatment of SR9009 prevented the onset of LPS-induced mechanical 
hypersensitivity, cytokine expression and GFAP expression. Intrathecal injection of 
3SR9009 also ameliorated mechanical hypersensitivity during the maintenance phase 
of complete Freund’s adjuvant-induced inflammatory pain and partial sciatic nerve 
ligation-, paclitaxel-, and streptozotocin-induced neuropathy in mice. The current 
findings suggest that spinal astrocytic REV-ERBs could be critical in the regulation of 
nociceptive transduction through downregulation of pronociceptive molecule 
expression. Thus, spinal REV-ERBs could be an effective therapeutic target in the 
treatment of chronic pain.
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5Introduction 
 There are an increasing number patients suffering from chronic pain, including 
neuropathic and inflammatory pain, which is associated with the growing population of 
elderly people (Ferreira and de Luca, 2017; Gagliese et al., 2017). In addition, for 
many of these patients, chronic pain is refractory to treatment with commonly used 
analgesics such as opioids and non-steroidal anti-inflammatory drugs. A number of 
studies have shown that dysregulation of the expression of a number of 
pronociceptive factors such as pro-inflammatory cytokines and chemokines in CNS 
glial cells contribute to the induction and maintenance of chronic pain (Grace et al., 
2014; Ji et al., 2016). While antagonists, neutralizing antibodies and synthesis 
blockers to pronociceptive molecules show varying degrees of efficacy in a range of 
chronic pain models, the analgesic effects of these reagents alone are not always 
robust. This suggests that targeting mechanisms that regulate the production of 
numerous molecules rather than targeting specific molecules may be crucial in 
alleviating chronic pain.
REV-ERBα and REV-ERBβ (REV-ERBs) are orphan nuclear receptors encoded by 
NR1D1 and NR1D2, respectively, which are expressed in various cell types (Kojetin 
and Burris, 2014). It has been demonstrated that REV-ERBs have crucial functions in 
the regulation of metabolism, inflammation and tumor growth (Sato et al., 2014; Solt et 
6al., 2012; Sulli et al., 2018). Like other nuclear receptors, REV-ERBs exert a ligand-
dependent inhibitory effect on gene transcription of various molecules (Kojetin and 
Burris, 2014; Yin and Lazar, 2005). Accumulating evidence has shown that REV-
ERBs negatively regulate the expression of various proinflammatory molecules such 
as the cytokine interleukin-6 (IL-6) and the chemokine CCL2, following binding of the 
synthetic REV-ERB-specific agonists GSK4112 and SR9009 in macrophages (Sato et 
al., 2014; Sitaula et al., 2015). A previous finding showed mildly increased mechanical 
nociceptive sensitivity in REV-ERBα knockout mice (Lee et al., 2016). Furthermore, it 
is possible that REV-ERBs might be a new target as analgesic for osteoarthritis-
induced pain (Das et al., 2018). However, the exact function and role of REV-ERBs in 
nociceptive transduction under chronic pain states has yet to be elaborated.
Over-activation of astrocytes in spinal dorsal horn contributes to the maintenance of 
chronic pain (Morioka et al., 2015; Zhuang et al., 2005). Production of pronociceptive 
molecules by spinal astrocytes could lead to persistent nociceptive hypersensitivity 
(Gao et al., 2009; Mika et al., 2013; Nakagawa and Kaneko, 2010). Intrathecal 
administration of fluorocitrate, an astrocytic inhibitor, ameliorated nociceptive 
hypersensitivity in chronic pain models (Shibata et al., 2011; Zhang et al., 2012b). 
These observations suggest that modulating spinal astrocytic activity, from an 
abnormal or pathophysiological state back to the normal, physiological state, could be 
7crucial in reducing or eliminating nociceptive hypersensitivity.
Stimulation of REV-ERBs expressed in C6 astroglioma cells suppressed cytokine 
tumor necrosis factor (TNF)-induced expression of both CCL2 and matrix 
metalloprotease-9 (MMP-9) (Morioka et al., 2016b). However, a role for REV-ERBs in 
regulating spinal astrocytic function and in nociceptive transduction in particular has 
yet to be elaborated. Thus, the current study examined the effects of synthetic REV-
ERBs specific agonists SR9009 and GSK4112 on REV-ERBs expressed on spinal 
astrocytes. The endotoxin lipopolysaccharide (LPS) elicits robust neuroinflammation 
in animal models and is widely used to induce inflammatory pain through activation of 
astrocytes in the CNS (Li et al., 2014; Lu et al., 2015). The current study examined the 
effect of REV-ERBs specific agonists on LPS-induced expression of pro-nociceptive 
molecules by spinal astrocytes and the antinociceptive effects of SR9009 on LPS-
induced mechanical hypersensitivity and inflammatory and neuropathic pain in mice.
8Materials and Methods
Animals
All experiments utilizing animals were conducted in accordance with the “Guidelines 
for the Care and Use of Laboratory Animals” established by The Japanese 
Pharmacological Society and Hiroshima University, and procedures were reviewed 
and approved by the Committee of Research Facilities for Laboratory Animal Science 
of Hiroshima University.
Pregnant Wistar rats (13 days) were obtained from Japan SLC, Inc. (Shizuoka, 
Japan) and 1-day old pups of both sexes were obtained from these rats. Male ddy 
mice, 6 weeks of age (Japan SLC, Inc.) were maintained in a vivarium, room 
temperature of 22±2℃, with a 12h light/dark cycle (lights on/off at 8:00 AM/8:00 PM), 
and given access to food and water available ad libitum during the experimental 
period. 
Reagents
 Lipopolysaccharide was obtained from Sigma Chemical Co. (St. Louis, MO, USA). 
SR9009, a REV-ERBs agonist (REV-ERBα EC50=0.67 μM, REV-ERBβ EC50=0.8 μM 
(Solt et al., 2012)), was obtained from Merck Millipore (Darmastadt, Germany). 
GSK4112 was purchased from Cayman Chemical (Ann Arbor, MI). GSK4112 is a 
9synthetic REV-ERBs agonist (The 50% effective concentration (EC50) to REV-ERBα is 
0.4 μM. The EC50 to REV-ERBβ is not known.) (Grant et al., 2010). RGFP966 is a 
selective histone deacetylase 3 (HDAC3) inhibitor (50% inhibitory concentration 
(IC50)=0.08 μM), and is reported to have no affinity to other types of HDAC (IC50>15 
μM). GSK4112, SR9009 and RGFP966 were dissolved in DMSO to a final 
concentration of 0.1% DMSO. Recombinant rat TNF was obtained from WAKO Pure 
Chemical Industries (Osaka, Japan). TNF was dissolved in distilled H2O. Paclitaxel 
was obtained from Sawai Pharmaceutical Co., Ltd. (Osaka, Japan).
Cell culture
The preparation of cultured spinal astrocytes has been described previously 
(Morioka et al., 2018). In brief, spinal cords isolated from neonatal Wistar rats were 
minced, and then incubated with trypsin and DNase Ⅰ . Dissociated cells were 
suspended in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal calf serum (FCS) and penicillin/streptomycin (100 units/ml and 100 μg/ml, 
respectively). Thereafter, cell suspensions were plated in 75cm2 tissue culture flasks 
(7.5-10×106 cells/flask) precoated with poly-L-lysine (10 μg/ml). Cells were 
maintained in a 10% CO2 incubator at 37℃. After 10 days, the flasks containing mixed 
glial cells were vigorously shaken and washed with PBS to remove microglial cells. 
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Remaining cells were trypsinized, and seeded to new flasks. After confluent state, 
cells were treated with 1 μM of cytosine β-D-arabinofuranoside (Sigma) to prevent 
proliferation of other cells such as microglia and fibroblasts for 2 days. Then, the 
flasks were again vigorously shaken and washed, and the cells were trypsinized. 
Thereafter, the remaining cells were transferred to 35-mm dishes (3-3.5×105 cells). 
After 3 days, the medium was replaced with DMEM without FCS and antibiotics. After 
an additional 24 hours of incubation, the cells were used in experiments. Greater than 
95% of the cells obtained using the current method expressed an astrocytic 
phenotype as confirmed by RT-PCR and Western blotting (Morioka et al., 2014).
Rat cultured spinal astrocytes have been shown to express Rev-erbα mRNA and 
Rev-erbβ mRNA (Morioka et al., 2016b). To induce expression of pro-nociceptive 
molecules, cells were incubated with either LPS (10 ng/ml) or TNF (10 ng/ml). The 
role of REV-ERBs in LPS-induced gene expression was assessed using 
pharmacological agents. Compounds that activated REV-ERB were incubated in 
astrocytes for 30 min followed by LPS or TNF incubation for up to 24 hours. Cell 
medium and cells were removed for assay at specific time points during LPS or TNF 
incubation (see Results).
Real-time PCR analysis
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cDNA synthesized using 1 μg of total RNA from cultured spinal astrocytes and mice 
spinal tissue were subjected to real-time PCR assay with specific primers and 
EXPRESS SYBR® GreenERTM qPCR SuperMix (Invitrogen, Carlsbad, CA, USA). The 
sequences of the primers are described in previous reports (Morioka et al., 2018; 
Zhang et al., 2016). Real-time PCR assays were conducted using a DNA engine 
Opticon 2 real-time PCR detection system (Bio-Rad, Hercules, CA, USA). The three-
step amplification protocol consisted of 3 min at 95℃ followed by 40 cycles of 95℃ 
for 15 s, 60℃  for 30 s, and 72℃  for 30 s. RNA quantification of target genes was 
calculated using the Ct method. The Ct values of each amplification were normalized 
to those obtained with the amplification of glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH).
Transfection of primary cultured astrocytes with small interfering RNA (siRNA)
 Forty-eight hours after the cells were seeded, the culture was replaced with Opti-
MEM medium (Invitrogen, Carlsbad, CA, USA), and then the cells were transfected 
with either siRNA, targeting rat Rev-erbα (siGENOME SMARTpool, Rat Nr1d1, GE 
Dharmacon, Lafayette, CO, USA), Rev-erbβ (siGENOME SMARTpool, Rat Nr1d2, 
GE Dharmacon) or non-targeting siRNA (siGENOME Non-Targeting siRNA Pool #2) 
by using Lipofectamine RNAi MAX reagent (Invitrogen). Twenty-four hours after 
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transfection, cells were treated with SR9009 for 30 min. Then, cells were further 
treated with LPS for 24 hours. 
ELISA
 Rat IL-1β, IL-6 and CCL2 protein levels in cell-conditioned medium were measured 
using ELISA kits (eBioscience, San Diego, CA, USA). After treatment with SR9009 for 
30 min, astrocytes were stimulated with LPS for 24 hours. Then, culture media were 
immediately collected and stored at -80℃ until assay. Each reaction was performed 
according to the manufacturer’s protocol.
Gelatin zymography
 To measure the activity of MMP-9, a gelatinase, gelatin zymography was performed 
based on methods described previously (Abe et al., 2016). In brief, after drug 
treatment, the culture supernatant of primary astrocytes was collected, and the 
supernatant was added to sample buffer (125 mM Tris-HCl, pH 6.8, 1% glycerol, 2% 
SDS, 0.01% bromophenol blue), and equal amount of protein were separated by 
electrophoresis using 8% SDS-polyacrylamide gel containing 0.1% gelatin under non-
reducing condition. After separation, gels were incubated with 2.5% Triton X-100 for 1 
hour, and further incubated with the buffer (50 mM Tris-HCl (pH 7.4, 10 mM CaCl2, 
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0.02% NaN3) for 20 hours at 37℃ . Then, gels were incubated with the staining 
solution (0.125% Coomassie Brilliant Blue R-250, 30% ethanol, 10% acetic acid) for 3 
hours, and destained in 25% methanol/7.5% acetic acid until bands showing 
gelatinolysis are clearly appeared. The density of specific band for MMP-9 was 
identified dependent on the molecular size (83 kDa) of MMP-9 described previous 
study (Abe et al., 2016) and using by the MMP Marker (PMC Cosmobio, Tokyo, 
Japan). The density was measured with Science Lab Image Gauge (Fuji Film, Tokyo, 
Japan).
Mouse intrathecal injection
 Intrathecal injections were performed on unanesthetized mice. In brief, mice were 
restrained with the left hand and the injection was performed with the right hand. The 
vertebral landmarks for L5 and L6 vertebrate were identified by palpation. An injection 
into the subarachnoid space between the L5 and the L6 vertebrae was done via a 27-
gage needle. Entry of the needle was confirmed with the presence of a tail flick. The 
injection volume of all other compounds was 5 μl. 
Inflammatory pain models
 Inflammation was induced by either intrathecal injection of LPS (0.1 μg/5 μl saline) or 
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subcutaneous injection of complete Freund’s adjuvant (CFA; 30 μl, 1mg of 
Mycobacterium tuberculosis/ml, Sigma) into the center of the plantar surface of left 
hind-paw in mice. The same volume of saline was used as a control.
Partial sciatic nerve ligation (PSNL)-induced neuropathic pain model 
 Under sodium pentobarbital (50 mg/kg, i.p.) anesthesia, a tight ligation of 
approximately one-third to one-half of the diameter of the left sciatic nerve (ipsilateral) 
was performed with 8-0 silk suture as described previously (Morioka et al., 2016a). In 
sham-operated mice, the sciatic nerve was exposed but not ligation. Previous studies 
have demonstrated that mechanical hypersensitivity was observed 3 days, and lasted 
at 3 weeks following PSNL (Morioka et al., 2015; Nakamura et al., 2015).
Paclitaxel-induced neuropathic pain model
Paclitaxel was dissolved in cremophor:ethanol (1:1) as the stock solution (6 mg/ml). 
This was diluted in saline to a final concentration of 0.2 mg/ml. The vehicle for 
paclitaxel was diluted with saline at the same proportion as the paclitaxel solution. 
Then, paclitaxel (2 mg/kg) was intraperitoneally administered in a volume of 0.1 
mL/20 g once per day for 5 times every other day (cumulative dose 10 mg/kg).
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Diabetes-induced neuropathic pain model
Diabetes was induced in mice fasted overnight by an injection of streptozotocin 
(Cayman Chemical). Streptozotocin was dissolved in saline immediately before 
injection and the solution administered intraperitoneally at a dose of 200 mg/kg. 
Control animals received a vehicle injection. Blood samples were collected from tail 
vein, and blood glucose levels were measured by a glucometer (Freestyle Freedom 
Lite; NIPRO, Osaka, Japan). Hyperglycemic mice (>300 mg/dl) at 21 days after 
streptozotocin injection were used for further analysis. 
Hind paw sensitivity to mechanical stimulation 
 All behavioral assessments were performed blinded. The withdrawal threshold (in 
grams) of the hind paw to mechanical stimulation was determined using von Frey 
filaments (Morioka et al., 2015). In brief, a von Frey filament was pressed against the 
mid-planter surface of the hind paw. The lowest force that caused responses such as 
lifting and licking of the hind paw was assigned as the withdrawal threshold. Each hind 
paw was tested three times, at 10 second intervals, and the mean withdrawal 
threshold was reported. Mice with inflammation, PSNL or paclitaxel that did not show 
robust mechanical hypersensitivity, hind paw withdrawal threshold >0.1 g, were 
excluded from the experiments. Prior to treatment, hind paw withdrawal thresholds 
16
were 1.0±0.2 g (mean±SEM).
In LPS-treated mice, either 100 or 300 nmol of SR9009 or 100 nmol of GSK4112 
were intrathecally treated 1 hour before LPS injection. Withdrawal thresholds were 
measured 1, 2, 3, 6 and 24 hours following the second intrathecal injection. In CFA-
treated mice, 7 days following intraplantar treatment of CFA, mice received either an 
intrathecal treatment of 100 or 300 nmol of SR9009 or 100 nmol of GSK4112. 
Withdrawal thresholds were then measured 1, 2, 3, 6 and 24 hours post-injection. In 
PSNL mice, 14 days following surgery, mice received an intrathecal treatment of 100 
or 300 nmol of SR9009. Withdrawal thresholds were then measured 1, 2, 3, 4, 5 and 
24 hours post-injection. In paclitaxel mice, 14 days following the injection (6 days 
following the last injection), mice received an intrathecal treatment of 100 or 300 nmol 
of SR9009. Withdrawal thresholds were then measured 1, 2, 3, 6 and 24 hours post-
injection. In diabetic mice, 21 days following the injection of streptozotocin, mice 
received an intrathecal treatment of 100 or 300 nmol of SR9009. Withdrawal 
thresholds were then measured 1, 2, 3, 6 and 24 hours post-injection.
Immunohistochemistry
 Tissue sections of spinal dorsal horn from at least 3 mice of each treatment were 
used for immunohistochemistry. Thirty minutes after intrathecal administration of 
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SR9009, mice were further intrathecally injected of LPS. Fourteen days following 
PSNL, SR9009 was intrathecally injected. Then, after 3 hours, mice were 
anesthetized with isoflurane (induction; 5%, maintenance; 2-3%) and sodium 
pentobarbital (50 mg/kg, i.p.). Mice were transcardially perfused with 50 ml of saline 
followed by 100 ml of freshly prepared 4% (w/v) paraformaldehyde in 0.1 M 
phosphate buffer (pH = 7.4). The spinal tissues were quickly removed and postfixed in 
4% paraformaldehyde in 0.1 M phosphate buffer for three days at 4°C and then 
cryoprotected overnight in 30% (w/v) sucrose in 0.1 M phosphate buffer at 4°C. 
Tissues were embedded in Tissue-Tek OCT compound 4583 (Sakura Finetech, 
Tokyo, Japan) and frozen in liquid nitrogen, cut serially (20 μm thickness) in a 
cryostat, and collected onto glass slides. After slides were dried at room temperature, 
tissue sections were processed for double-labeling immunohistochemistry. Tissue 
sections were rinsed with phosphate-buffered saline, incubated in a blocking solution 
of 10% goat serum, 3% bovine serum albumin, 0.1% Triton X and 0.05% Tween-20 in 
phosphate-buffered saline for 2 hours at room temperature, and then incubated with 
rabbit anti-glial fibrillary acidic protein (GFAP) antibody (1:1,000, GTX72747, 
GeneTex Inc., Irvine, CA, USA). Tissues were incubated in primary antibodies for 72 
hours at 4°C, followed by corresponding secondary antibodies conjugated with Alexa 
Fluor® 488 (1:500) for 2 hours at 4°C in a dark chamber. The sections were then 
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extensively washed in phosphate-buffered saline and coverslipped. Sections were 
examined with a BZ-9000 Biorevo all-in-one fluorescence microscope (Keyence, 
Elmwood Park, NJ, USA). 
Statistical analysis
Data are expressed as the mean±SEM of at least three independent determinations. 
The effects of drug treatment on mRNA and protein levels were performed using a 
one-way analysis of variance (ANOVA) with a pairwise comparison by the Tukey-
Kramer method. Comparisons between two groups were performed using Student’s t-
test. Possible interactions between treatment over time on mechanical 
hypersensitivity were analyzed by two-way repeated-measures ANOVA, followed by 
the Tukey-Kramer method for post hoc comparisons. Differences were considered to 
be significant when the P value was less than 0.05.
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Results
REV-ERBs agonists block LPS-induced production of pronociceptive 
molecules in cultured spinal astrocytes
 Treatment of cultured spinal astrocytes with LPS markedly upregulated mRNA 
expression of pro-nociceptive molecules, including IL-1β, IL-6, MMP-9 and CCL2 (Fig. 
1a-1d). Induction of IL-β mRNA expression was observed 1 hour, peaked 6 hours and 
declined 24 hours after treatment with LPS (Fig. 1a). The inhibitory effect of a specific 
REV-ERBs agonist SR9009 on LPS-induced IL-β mRNA expression was observed 
beginning 1 hour after treatment with LPS, and this effect lasted over the 24 hours 
incubation period (Fig. 1a). Although LPS-induced IL-6 mRNA expression was also 
observed 1 hour after LPS incubation, induction of IL-6 mRNA was significantly 
prevented by pretreatment with SR9009 at 6 and 24 hours (Fig. 1b). MMP-9 mRNA 
expression was significantly induced 3 hours after LPS treatment, and inhibitory effect 
of SR9009 on the MMP-9 mRNA expression was also observed at the same time and 
this effect lasted 24 hours (Fig. 1c). Induction of CCL2 mRNA was observed 1 hour 
after LPS treatment--SR9009 had no effect on LPS-induced CCL2 mRNA expression 
(Fig. 1d). Incubation of cultured spinal astrocytes with 10 μM of SR9009 alone did not 
significantly affect mRNA expression of pronociceptive molecules (Fig. 1). 
Pretreatment with SR9009 (3, 5 and 10 μM) significantly suppressed the stimulatory 
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effects of LPS on IL-1β mRNA, IL-6 mRNA and MMP-9 mRNA in a concentration-
dependent manner (Fig. 2a-2c). Although SR9009 slightly inhibited LPS-induced 
CCL2 mRNA expression, this effect was not statistically significant (Fig. 2d). 
Furthermore, pretreatment with 10 and 20 μM of GSK4112, also a REV-ERB agonist, 
significantly suppressed LPS-induced mRNA expression of IL-1β, IL-6, MMP-9, but 
not CCL2 (Fig. 3a-3d). Incubation of cultured spinal astrocytes with 20 μM of 
GSK4112 alone did not significantly affect mRNA expression of pronociceptive 
molecules (Fig. 3). In addition, pretreatment with SR9009 also significantly blocked 
TNF-induced mRNA expression of IL-1β, IL-6 and MMP-9 (Fig. 4a-4c). In TNF-treated 
cells, similar to that observed following LPS treatment, SR9009 showed a trend 
towards inhibition of CCL2 mRNA expression, which was not statistically significant 
(Fig. 4d). 
SR9009 inhibited LPS-induced protein expression of IL-1β, IL-6, CCL2 and MMP-9. 
Treatment with SR9009 (10 μM) significantly inhibited LPS-induced production of IL-
1β, IL-6, but not CCL2 (Fig. 5a-5c). Furthermore, gelatin zymography showed that 
stimulation with LPS increased the activity of MMP-9 released into the cultured 
medium, and this effect was significantly blocked by pretreatment with SR9009 (Fig. 
5d). Incubation of cultured spinal astrocytes with 10 μM of SR9009 alone did not 
significantly affect protein expression of pronociceptive molecules (Fig. 5a-5d).
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As mentioned earlier, cultured spinal astrocytes express both Rev-erbα mRNA and 
Rev-erbβ mRNA (Morioka et al., 2016b), and SR9009 acts on both types of REV-
ERBs with almost equal affinity (Solt et al., 2012). Thus, siRNA was used to inhibit 
expression of Rev-erbα mRNA and Rev-erbβ. As shown in Fig. 6a, the expression of 
both Rev-erbα mRNA and Rev-erbβ mRNA in cultured spinal astrocytes was 
significantly reduced after 48 hours of incubation with both siRNAs. Although 
significant inhibition by SR9009 on LPS-induced expression of IL-1β mRNA and 
MMP-9 mRNA was observed following knockdown of both Rev-erbs, the inhibitory 
effects of SR9009 were significantly reduced (Fig. 6b, 6d). Significant knockdown of 
both Rev-erbs mRNA almost completely reversed inhibitory effect of SR9009 on LPS-
induced IL-6 mRNA expression (Fig. 6c). Thus, these results demonstrate that 
stimulation of REV-ERBs prevent the expression of pro-nociceptive molecules in 
spinal astrocytes. 
Histone deacetylase 3 is a crucial mediator of the inhibitory effects of REV-
ERBs on LPS-induced mRNA upregulation of IL-1β and IL-6, but not MMP-9, in 
cultured spinal astrocytes
Previous studies have demonstrated that REV-ERBs repress gene transcription 
through recruitment of nuclear receptor corepressor 1 (NCoR1) and HDAC3. Thus, 
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astrocytes were pretreated with the HDAC3 inhibitor RGFP966. RGFP966 (2 μM) 
reversed the inhibitory effect of SR9009 on LPS-induced expression of IL-1β mRNA 
and IL-6 mRNA (Fig. 7a, 7b). However, pretreatment with RGFP966 did not reverse 
LPS-induced expression of MMP-9 mRNA (Fig. 7c). Treatment with RGFP966 alone, 
without LPS and SR9009, did not affect IL-1β, IL-6 and MMP-9 mRNA expression. 
These results indicate that HDAC3 is necessary in the inhibitory effect of REV-ERBs 
on inducing IL-1β and IL-6 transcription with LPS. However, in the case of LPS-
induced MMP-9 transcription, molecular mechanisms other than HDAC3 could be 
involved in the inhibitory effect of REV-ERB.
Stimulation of spinal REV-ERBs with specific agonists prevents LPS-induced 
mechanical hypersensitivity through downregulation of pronociceptive 
molecules 
 Potential antinociceptive effects of the activation of spinal REV-ERBs on LPS-
induced hind paw mechanical hypersensitivity were examined. Intrathecal treatment 
with LPS induced significant mechanical hypersensitivity beginning 1 hour after 
injection, and lasted for as long as 24 hours after injection (Fig. 8). Intrathecal 
pretreatment with either SR9009 (100 and 300 nmol) or GSK4112 (100 nmol) 
prevented the onset of LPS-induced mechanical hypersensitivity (Fig. 7a; LPS versus 
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LPS+SR9009 100 nmol; F1,144=15.3, P<0.001, interaction effect, F1,144=3.36, 
P=0.00669, LPS versus LPS+SR9009 300 nmol; F1,159=47.4, P<0.001, interaction 
effect, F1,159=6.00, P<0.001, LPS versus LPS+GSK4112 100 nmol; F1,127=14.5, 
P<0.001, interaction effect, F1,127=5.17, P<0.001). Treatment with SR9009 alone had 
no effect on withdrawal thresholds of saline-treated mice (Fig. 8).
The effect of SR9009 on the expression of IL-1β, IL-6 and MMP-9 in spinal dorsal 
horn of mice following intrathecal treatment with LPS was examined. As the current 
study showed that antinociception with SR9009 was at least observed between 2-6 
hours following administration of LPS, the effect of SR9009 on pronociceptive 
molecules expression was examined 3 hours after intrathecal treatment with LPS. The 
expression of both IL-1β and IL-6 mRNA was significantly increased in spinal dorsal 
horn following LPS treatment (Fig. 9a and 9b). Intrathecal pretreatment with SR9009 
(100 and 300 nmol) significantly reduced both IL-1β and IL-6 mRNA expression in 
mice spinal dorsal horn treated with LPS (Fig. 9a and 9b). Intrathecal pretreatment 
with SR9009 alone did not change either IL-1β or IL-6 mRNA expression (Fig. 9a and 
9b). In contrast to in vitro findings, intrathecal treatment with LPS did not significantly 
induce MMP-9 mRNA expression. Intrathecal SR9009 treatment in mice either with or 
without intrathecal LPS treatment did not affect MMP-9 mRNA expression (Fig. 9c).
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Intrathecal treatment with SR9009 prevents LPS-induced GFAP expression in 
spinal dorsal horn
 An increase of GFAP immunoreactivity, a cellular marker for astrocytes, was 
observed in the spinal dorsal horn 3 hours following intrathecal injection of LPS, 
indicating the presence of activated astrocytes. Intrathecal saline injection did not 
change GFAP expression. Mice were intrathecally pretreated with SR9009 (300 nmol) 
and 30 min later were intrathecally injected with LPS. SR9009 prevented LPS-induced 
GFAP expression in spinal dorsal horn (Fig. 10). The findings suggest that activation 
of REV-ERBs prevents astrocytic activation.
Effect of SR9009 on mechanical hypersensitivity in mouse models of 
inflammatory and neuropathic pain 
The effect of SR9009 on CFA-induced peripheral inflammatory pain was investigated 
(Fig. 11a). After 7 days, intraplantar injection of CFA significantly decreased 
withdrawal thresholds to mechanical stimuli, indicating mechanical hypersensitivity 
(Fig. 11a). Intrathecal treatment with SR9009 (300 nmol) significantly ameliorated 
CFA-induced mechanical hypersensitivity (CFA versus CFA+SR9009 300 nmol; 
F1,108=34.2, P<0.001, interaction effect, F1,108=4.03, P=0.00215). Antinociceptive 
effect of SR9009 was observed beginning 2 hours after injection, and sustained for at 
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least 3 hours after injection (Fig. 11a). Treatment of saline-treated mice with SR9009 
had no effect on withdrawal thresholds (Fig. 11a).
A potential antinociceptive effect of SR9009 on various types of neuropathic pain 
(PSNL, paclitaxel and streptozotocin) was examined. Fourteen days after surgery, 
intrathecal injection of SR9009 significantly reversed mechanical hypersensitivity in a 
dose-dependent manner in PSNL mice (Fig. 11b; PSNL versus PSNL+SR9009 100 
nmol; F1,155=42.5, P<0.001, interaction effect, F1,155=12.0, P<0.001, PSNL versus 
PSNL+SR9009 300 nmol; F1,151=74.3, P<0.001, interaction effect, F1,151=14.1, 
P<0.001). The antinociceptive effect of 300 nmol SR9009 was observed beginning 2 
hours after injection and sustained for at least 3 hours after injection. Intrathecal 
injection of SR9009 (100 nmol) also significantly increased withdrawal thresholds to 
mechanical stimuli for about 3 hours after injection in PSNL mice (Fig. 11b). 
Intrathecal treatment with SR9009 (300 nmol) in sham-operated mice had no effect on 
withdrawal thresholds (Fig. 11b). 
 Significant mechanical hypersensitivity was observed 14 days following the first 
injection of paclitaxel (Fig. 11c). Intrathecal treatment with SR9009 significantly 
ameliorated paclitaxel-induced mechanical hypersensitivity (Fig. 11c; paclitaxel 
versus paclitaxel+SR9009 100 nmol; F1,72=117.94, P<0.001, interaction effect, 
F1,72=9.00, P<0.001). The antinociceptive effect of 100 nmol SR9009 was significant 
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beginning 1 hour after injection and lasted for at least 6 hours after injection (Fig. 11c). 
By contrast, the antinociceptive effect of 300 nmol SR9009 was observed 2 hours 
after injection (Fig. 11c). Intrathecal injection of SR9009 (300 nmol) in vehicle-treated 
mice had no effect on withdrawal thresholds (Fig. 11c).
Significant mechanical hypersensitivity was observed three weeks following the 
injection of streptozotocin (Fig. 11d). Intrathecal treatment with 300 nmol of SR9009 
significantly ameliorated streptozotocin-induced mechanical hypersensitivity (Fig. 
11d; streptozotocin versus streptozotocin+SR9009 300 nmol; F1,66=82.9, P<0.001, 
interaction effect, F1,66=22.2, P<0.001). The antinociceptive effect of 300 nmol 
SR9009 was observed beginning 2 hours after injection, and lasted for at least 3 
hours after injection (Fig. 11d). By contrast, no antinociceptive effect was observed 
with 100 nmol SR9009 (Fig. 11d). Intrathecal injection of SR9009 (300 nmol) in 
vehicle-treated mice had no effect on withdrawal thresholds (Fig. 11d).
Intrathecal treatment with SR9009 reverses upregulation of GFAP in spinal 
dorsal horn following sciatic nerve injury
 Fourteen days following PSNL, during the period of significant mechanical 
hypersensitivity, spinal dorsal horn GFAP expression was significantly increased 
compared than that of sham mice (Fig. 12a and 12b). Treatment with SR9009 (300 
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nmol) significantly suppressed PSNL-induced GFAP expression in spinal dorsal horn 
(Fig. 12a and 12b). Treatment with vehicle or SR9009 alone had no effect on GFAP 
expression in spinal dorsal horn of sham mice (Fig. 12a and 12b).
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Discussion
 The current study examined whether REV-ERBs could be targeted to relieve pain in 
various chronic pain states. In the current study, activation of cultured spinal 
astrocytes’ REV-ERBs prevented the expression of pronociceptive molecules by an 
inflammatory stimulus. During the maintenance phase of chronic pain, pronociceptive 
molecules produced by activated spinal astrocytes have a crucial role in mediating 
nociceptive hypersensitivity. In mice, activation of spinal REV-ERBs prevented LPS-
induced mechanical hypersensitivity through the downregulation of IL-1β and IL-6 
expression in spinal dorsal horn. Furthermore, activation of spinal REV-ERBs in mice 
reversed inflammatory and neuropathic mechanical hypersensitivity. In addition, 
stimulation of spinal REV-ERBs blocked upregulation of astrocytic activation marker 
protein GFAP in spinal dorsal horn of inflammatory and neuropathic pain model mice. 
Thus, the current findings suggest that astrocytic REV-ERBs could be crucial in the 
regulation of nociceptive transduction through the inhibition of the production of 
pronociceptive molecules.
 Significant involvement of REV-ERBs in the regulation of the response to 
inflammatory stimulation has been previously reported. Activation of REV-ERBs 
suppressed TNF-induced expression of CCL2 mRNA and MMP-9 mRNA, but not IL-6 
mRNA and inducible nitric oxide synthase mRNA, in C6 glioma cells (Morioka et al., 
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2016b). REV-ERBs appear to modulate the expression of proinflammatory molecules 
of various immune cells. Co-treatment with SR9009 blocked LPS and interferon-γ-
induced expression of IL-6 mRNA and IL-1β mRNA in mouse bone marrow-derived 
macrophages and activation REV-ERBα blocked IL-6 and CCL2 expression in mouse 
peritoneal macrophage (Sato et al., 2014; Sitaula et al., 2015). Mutation of REV-ERBs 
in bronchial epithelia augmented inflammatory responses and chemokine production, 
demonstrating the importance of activated REV-ERBs in the response to 
inflammatory stimuli (Pariollaud et al., 2018). Although Rev-erb mRNA expression has 
been observed in cultured spinal astrocytes (Morioka et al., 2016b), there are no 
reports regarding the function of REV-ERB subtypes in spinal astrocytes. 
The current study demonstrated that activation of REV-ERBs expressed on cultured 
spinal astrocytes suppressed LPS-induced expression of IL-1β, IL-6 and MMP-9. The 
proinflammatory cytokine TNF, which is mainly produced from activated microglia, 
has been shown to induce the production of pronociceptive molecules and evoke 
mechanical hypersensitivity, possibly through the activation of spinal astrocytes 
(Grace et al., 2014; Morioka et al., 2014). In the current study, activation of spinal 
astrocytic REV-ERBs also prevented TNF-induced expression of IL-1β, IL-6 and 
MMP-9. Thus, it is possible that REV-ERBs could suppress activation of astrocytes 
regardless of the inflammatory stimulus. REV-ERBs activation partially inhibited 
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induction of CCL2 expression, indicating that REV-ERBs play a minor role in the 
expression of this pronociceptive molecule and further suggests that REV-ERBs 
modulate the expression of many but not all pronociceptive molecules. The inhibitory 
effects of REV-ERBs agonist SR9009 can be attributed to direct stimulation of REV-
ERBs, as knockdown of both subtypes of REV-ERB by RNA interference led to a lack 
of efficacy of the agonist and SR9009 has no significant cross-activity against other 
members of the nuclear receptor superfamily (Solt et al., 2012). Together, these 
findings indicate that activation of spinal astrocytic REV-ERBs have a significant role 
in mediating antinociception. 
REV-ERBs bind to retinoic acid receptor-related orphan receptors (RORs) element 
(RORE) and compete in binding of positive transcriptional factor RORs (Kojetin and 
Burris, 2014; Sato et al., 2014). Furthermore, it has been shown that the HDAC3-
dependent transcriptional inhibition by REV-ERB activation could be mediated 
through the modulation of response elements different from that of the RORE motif 
(Zhang et al., 2015). These are the potential mechanism mediating REV-ERBs 
inhibition of transcription. The current study showed that HDAC3 activity is crucial in 
the inhibitory effects of REV-ERBs on LPS-induced expression of IL-1β and IL-6, but 
not MMP-9. Thus, it is possible that the effect of REV-ERBs on MMP-9 in spinal 
astrocytes could be regulated by a RORs-dependent mechanism. By contrast, a 
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previous study demonstrated that the inhibitory effect of REV-ERBs on MMP-9 
induction is dependent on HDAC3 in C6 glioma cells (Morioka et al., 2016b). Thus, 
these findings suggest that a REV-ERBs-mediated inhibitory mechanism could be 
dependent whether a ROR element or HDAC3-acting sites exist in the promoter 
regions of the target gene in different cell types. 
Activated spinal astrocytes have a key role in the maintenance of nociceptive 
hypersensitivity during the chronic pain state, so targeting astrocytic activity could 
lead to significant analgesia. While there are a number of mechanistic distinctions 
between inflammatory and neuropathic pain, it has been found that activation of spinal 
astrocytes is crucial across these models (Deng et al., 2017; Morioka et al., 2015; 
Qian et al., 2016). In the case of paclitaxel-induced neuropathy and PSNL, 
mechanical hypersensitivity appears to be mainly mediated through activation of 
spinal dorsal horn astrocytes and not microglia (Li et al., 2014; Morioka et al., 2015; 
Zhang et al., 2012a). Intrathecal LPS-induced mechanical hypersensitivity is likely 
due to activation of astrocytes in spinal dorsal horn (Lu et al., 2015; Saito et al., 2010; 
Zhao et al., 2014) and in the current study activation of REV-ERBs reduced both LPS- 
and PSNL-induced GFAP expression in spinal dorsal horn as well as suppressed 
mechanical hypersensitivity in both pain model mice. It is possible, then, that the 
antinociceptive effect of REV-ERBs activation observed across the current set of 
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chronic pain models could be mediated, in part, by suppression of astrocytic 
activation. 
While astrocytic functional status, such as GFAP immunoreactivity, was not directly 
assessed in the neuropathic and inflammatory pain models in the current study, 
reduced astrocytic functioning following REV-ERBs activation was inferred by 
reduced production of pronociceptive cytokines (Grace et al., 2014; Hansen and 
Malcangio, 2013; Nakagawa and Kaneko, 2010). The current study confirmed 
previous finding, in that stimulation of spinal dorsal horn astrocytes in vivo with LPS 
upregulated pronociceptive molecules, including IL-1β and IL-6, (Lu et al., 2015; Zhao 
et al., 2014). Previous studies also showed that these molecules mediate LPS-
induced hypersensitivity (Loram et al., 2011; Zhu et al., 2014). In the current study, 
upregulation of IL-1β and IL-6 was prevented and mechanical hypersensitivity was 
reduced with intrathecal treatment with a REV-ERB agonist. Thus, the decreased 
expression of pronociceptive molecules and decreased mechanical hypersensitivity 
observed following spinal REV-ERBs activation suggests decreased spinal astrocytic 
activation. 
The inhibitory role of REV-ERBα in gene expression is well known. REV-ERBβ 
contributes to the regulation of genes involved in lipid and energy homeostasis in 
skeletal muscle cells (Ramakrishnan et al., 2005). Furthermore, several types of 
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tumor cell predominantly express REV-ERBβ, and genetic or pharmacological 
inhibition of REV-ERBβ sensitizes cancer cells to the cytotoxic reagent chloroquine, 
which suppresses autophagy (De Mei et al., 2015). In the current study, the inhibitory 
role of each REV-ERB on the expression of pronociceptive molecules was not clearly 
demarcated. Preliminary findings suggested that although knockdown of both REV-
ERBs by RNA interference prevented SR9009-induced suppression of gene 
expression in cultured spinal astrocytes, knockdown of either REV-ERB alone did not 
(data not shown). Thus, each REV-ERB subtype could have a distinct function in 
regulating IL-6, IL-1β and MMP-9 transcription in spinal astrocytes.
A number of studies demonstrated that activation of REV-ERBs suppresses MMP-9 
expression in various cell types (Lam et al., 2013; Morioka et al., 2016b; Song et al., 
2018; Stujanna et al., 2017). Interestingly, in the current study, while in vitro astrocytic 
expression of MMP-9 mRNA increased following LPS treatment, spinal dorsal horn 
MMP-9 expression was not changed following intrathecal LPS treatment. Therefore, it 
is possible that MMP-9 might not be involved in LPS-induced nociceptive 
hypersensitivity in vivo. Alternatively, it is possible that MMP-9 is involved in late-stage 
maintenance of LPS-induced hypersensitivity, as the current study found peak in vitro 
expression of MMP-9 mRNA was later than that of IL-1β mRNA and IL-6 mRNA. In 
vivo findings in inflammatory and neuropathic pain models suggest that spinal MMP-9 
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is likely involved in late-stage maintenance of pain (Jiang et al., 2017; Kular et al., 
2012). Although further investigation is needed, downregulation of MMP-9 could be 
one of the mechanisms underlying the antinociceptive effect of SR9009 and MMP-9 
could be an important molecule mediating established nociceptive hypersensitivity 
across a variety of pain states.
While the current study confirms a role of spinal astrocytes in the maintenance of 
chronic pain, activated spinal microglial REV-ERBs could also have an 
antinociceptive function. Intrathecal injection of LPS activates both spinal dorsal horn 
microglia and astrocytes (Saito et al., 2010; Zhao et al., 2014; Zhu et al., 2014). 
Treatment of cultured mouse brain microglia with the REV-ERB agonist SR9011 
suppressed LPS-induced IL-6 expression (Nakazato et al., 2017). Therefore, it is 
possible that spinal microglial REV-ERBs could modulate spinal IL-1β and IL-6 mRNA 
expression in the current study, thereby contributing to REV-ERB agonist-mediated 
antinociception observed in the current study. However, whether spinal microglial 
REV-ERBs regulate the expression of proinflammatory molecules is not unknown. 
 In conclusion, the current findings demonstrated that stimulation of spinal astrocytic 
REV-ERBs suppressed astrocytic functioning, as inferred by decreased production of 
pronociceptive molecules IL-1β and IL-6. Stimulation of spinal astrocytic REV-ERBs 
could be effective in a wide range of pain states as astrocytes have a key role in 
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mediating chronic pain, regardless of etiology. Therefore, targeting spinal astrocytic 
REV-ERBs could be a novel therapeutic strategy for ameliorating chronic pain. 
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Figure Legends
Figure 1. Suppressive effect of SR9009 on LPS-induced upregulation of IL-1β mRNA 
(a), IL-6 mRNA (b), MMP-9 mRNA (c) and CCL2 mRNA (d) expression over time in 
cultured spinal astrocytes. After treatment with REV-ERB agonist SR9009 (10 μM) for 
30 min, cells were then stimulated with LPS (10 ng/ml) for time periods indicated (1, 3, 
6 and 24 hours). Then, expression levels of each mRNA were determined. Data are 
expressed as ratio of vehicle at each corresponding time point, and represent the 
mean± SEM for five independent experiments. *P<0.05, **P<0.01 vs. vehicle 
treatment. †P<0.05, ††P<0.01 vs. LPS treatment alone.
Figure 2. Effect of SR9009 on LPS-induced upregulation of IL-1β mRNA (a), IL-6 
mRNA (b), MMP-9 mRNA (c) and CCL2 mRNA (d) expression in cultured spinal 
astrocytes. After treatment with REV-ERB agonist SR9009 (3, 5 or 10 μM) for 30 min, 
cells were then stimulated with LPS (10 ng/ml) for 24 hours. Cells were also treated 
with SR9009 in the absence of LPS. Data represent the mean±SEM for six to nine 
independent experiments. **P<0.01 vs. vehicle treatment. ††P<0.01 vs. LPS treatment 
alone.
Figure 3. Effect of GSK4112 on LPS-induced upregulation of IL-1β mRNA (a), IL-6 
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mRNA (b), MMP-9 mRNA (c) and CCL2 mRNA (d) expression in cultured spinal 
astrocytes. After treatment with REV-ERB agonist GSK4112 (10 or 20 μM) for 30 min, 
cells were then stimulated with LPS (10 ng/ml) for 24 hours. Cells were also treated 
with GSK4112 in the absence of LPS. Data represent the mean± SEM for five 
independent experiments. **P<0.01 vs. vehicle treatment. †P<0.05, ††P<0.01 vs. LPS 
treatment alone.
Figure 4. Effect of SR9009 on TNF-induced upregulation of IL-1β mRNA (a), IL-6 
mRNA (b), MMP-9 mRNA (c) and CCL2 mRNA (d) expression in cultured spinal 
astrocytes. After treatment with SR9009 (3 or 5 μM) for 30 min, cells were then 
stimulated with TNF (10 ng/ml) for 24 hours. Cells were also treated with SR9009 in 
the absence of TNF. Data represent the mean± SEM for five independent 
experiments. **P<0.01 vs. vehicle treatment. †P<0.05, ††P<0.01 vs. LPS treatment 
alone.
Figure 5. Effects of SR9009 on LPS-induced upregulation of proinflammatory 
molecule protein expression in cultured spinal astrocytes. Effects of SR9009 on LPS-
induced expression of IL-1β (a), IL-6 (b) and CCL2 (c) protein in cultured spinal 
astrocytes. After treatment with SR9009 (10 μM) for 30 min, cells were then 
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stimulated with LPS (10 ng/ml) for 24 hours. The expression levels of these proteins 
were measured by ELISA. Data represent the mean± SEM for four independent 
experiments. *P<0.05, **P<0.01 vs. vehicle treatment. †P<0.05, ††P<0.01 vs. LPS 
treatment alone. (d) Effects of SR9009 on LPS-induced MMP-9 activity in cultured 
spinal astrocytes. After treatment with SR9009 (10 μM) for 30 min, cells were then 
stimulated with LPS (10 ng/ml) for 24 hours. The activity of MMP-9 was measured by 
zymography. The upper photograph is a representative zymography of MMP-9. 
Quantitative graph are shown below. Data represent the mean± SEM for six 
independent experiments. **P<0.01 vs. vehicle treatment. †P<0.05 vs. LPS treatment 
alone.
Figure 6. REV-ERB activation is involved in the suppressed expression of 
proinflammatory molecules in cultured spinal astrocytes. (a) Silencing of Rev-erbα 
and Rev-erbβ expression in cultured spinal astrocytes. Cells were transfected with 
either non-targeting siRNA or a combination of Rev-erbα- and Rev-erbβ-tageting 
silencing interfering RNA (Rev-erbα/β siRNA). After 24 hours, Rev-erb mRNA 
expression levels were examined. Data represent the mean± SEM for five 
independent experiments. **P<0.01 vs. non-targeting siRNA treatment. 
Downregulation of Rev-erbs expression by siRNA prevented the inhibitory effect of 
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SR9009 on LPS-induced upregulation of IL-1β mRNA (b), IL-6 mRNA (c) and MMP-9 
mRNA (d) expression in cultured spinal astrocytes. After transfection with either non-
targeting siRNA or a combination of Rev-erbα- and Rev-erbβ-targeting siRNA for 24 
hours, astrocytes were treated with 5 μM of SR9009 for 30 min. Cells were then 
treated with 10 ng/ml of LPS for 24 hours. Data represent the mean±SEM for five 
independent experiments. **P<0.01 vs. LPS alone at each siRNA treatment. †P<0.05, 
††P<0.01 vs. LPS + SR9009 at non-targeting siRNA.
Figure 7. HDAC3 is involved in REV-ERB-mediated inhibition of IL-1β mRNA and IL-6 
mRNA expression, but not MMP-9 mRNA expression. After treatment with the 
selective HDAC3 inhibitor RGFP966 (2 μM) for 30 min, cells were incubated with 
SR9009 (5 μM) for 30 min and then LPS (10 ng/ml) for 24 hours. Cells were also 
incubated in RGFP966 (2 μM) in the absence of SR9009 and LPS. Expression levels 
of L-1β mRNA (a), IL-6 mRNA (b) and MMP-9 mRNA (c) relative to LPS-treated 
astrocytes are shown. Data represent the mean±SEM for five to eight independent 
experiments. **P<0.01 vs. vehicle treatment. †P<0.05, ††P<0.01 vs. LPS treatment 
alone. ##P<0.01 vs. SR9009+LPS treatment.
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Figure 8. REV-ERBs agonists prevent mechanical hypersensitivity of mice 
intrathecally injected with LPS. One hour after intrathecal treatment with either 
SR9009 (100 or 300 nmol), GSK4112 (100 nmol) or DMSO, either LPS (0.1 μg) or 
saline was intrathecally injected and hind paw withdrawal thresholds were assessed 
over time. n=10-13/group. Data represent the mean±SEM. *P<0.05, **P<0.01 vs. 
saline-injected mice with DMSO at the corresponding time point. †P<0.05, ††P<0.01 
vs. LPS-injected mice with DMSO at the corresponding time point. 
Figure 9. Activation of REV-ERBs reduces expression of IL-1β mRNA and IL-6 mRNA 
in spinal dorsal horn of mice intrathecally injected with LPS. Thirty minutes after 
intrathecal treatment with either SR9009 (100 or 300 nmol) or DMSO, either LPS (0.1 
μg) or saline was intrathecally injected. Three hours later, spinal dorsal horn 
expression levels of L-1β mRNA (a), IL-6 mRNA (b) and MMP-9 mRNA (c) were 
measured. n=7-10/group. Data represent the mean± SEM. **P<0.01 vs. saline-
injected mice with DMSO. †P<0.05, ††P<0.01 vs. LPS-injected mice with DMSO.
Figure 10. Activation of REV-ERB prevents GFAP expression in spinal dorsal horn of 
mice intrathecally injected with LPS. (a) Thirty minutes after intrathecal treatment with 
either SR9009 (300 nmol) or DMSO, either LPS (0.1 μg) or saline was intrathecally 
49
injected. Spinal dorsal horn was harvested 3 hours after LPS injection. Magnified 
photomicrographs of the white boxed areas are to the right. Scar bar=100 μm. (b) 
Quantitative analysis of expression of GFAP in spinal dorsal horn after injection of 
drugs described above at 3 hours following LPS injection. Data indicate mean ratio of 
sum of GFAP immunofluorescence intensity in each mice, and expressed as mean±
SEM for six to eight mice. **P<0.01 vs. saline-injected mice with DMSO. †P<0.05 vs. 
LPS-injected mice with DMSO.
Figure 11. Activation of REV-ERBs ameliorates mechanical hypersensitivity in mouse 
models of both inflammatory and neuropathic pain. a) Seven days after intraplantar 
treatment with either CFA or saline, either SR9009 (100 or 300 nmol) or DMSO was 
intrathecally injected and hind paw withdrawal thresholds were assessed over time. 
n=10/group. Data represent the mean±SEM. **P<0.01 vs. saline-injected mice with 
DMSO at the corresponding time point. ††P<0.01 vs. CFA-injected mice with DMSO at 
the corresponding time point. b) Fourteen days after sciatic nerve injury, either 
SR9009 (100 or 300 nmol) or DMSO was intrathecally injected and hind paw 
withdrawal thresholds were assessed over time. n=11-14/group. Data represent the 
mean±SEM. **P<0.01 vs. sham mice with vehicle at the corresponding time point. 
†P<0.05, ††P<0.01 vs. PSNL mice with vehicle at the corresponding time point. c) 
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Fourteen days after intraperitoneal treatment with either paclitaxel (PTX) or vehicle (6 
days after last injection), either SR9009 (100 or 300 nmol) or DMSO was intrathecally 
injected and hind paw withdrawal thresholds were assessed over time. n=5-8/group. 
Data represent the mean±SEM. *P<0.05, **P<0.01 vs. vehicle-injected mice with 
DMSO at the corresponding time point. †P<0.05, ††P<0.01 vs. PTX-injected mice with 
DMSO at the corresponding time point. d) Twenty one days after intraperitoneal 
treatment with either streptozotocin (STZ) or saline, either SR9009 (100 or 300 nmol) 
or DMSO was intrathecally injected and hind paw withdrawal thresholds were 
assessed over time. n=5-9/group. Data represent the mean± SEM. **P<0.01 vs. 
vehicle-injected mice with DMSO at the corresponding time point. ††P<0.01 vs. PTX-
injected mice with DMSO at the corresponding time point.
Figure 12. Activation of REV-ERB prevents GFAP expression in spinal dorsal horn of 
mice with PSNL. (a) Fourteen days after sciatic nerve injury, either SR9009 (300 
nmol) or DMSO was intrathecally injected. Spinal dorsal horn was harvested 3 hours 
after SR9009 injection. Magnified photomicrographs of the white boxed areas are to 
the right. Scar bar=100 μm. (b) Quantitative analysis of expression of GFAP in spinal 
dorsal horn after injection of drugs described above at 3 hours following SR9009 
injection. Data indicate mean ratio of sum of GFAP immunofluorescence intensity in 
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each mice, and expressed as mean±SEM for six to eight mice. *P<0.05 vs. saline-
injected mice with DMSO. †P<0.05 vs. LPS-injected mice with DMSO.
Highlights
1. REV-ERB agonist SR9009 prevented upregulation of pronociceptive 
molecules in spinal astrocytes.
2. Intrathecal treatment with SR9009 prevented LPS-induced mechanical 
hypersensitivity.
3. Intrathecal SR9009 treatment prevented LPS-induced GFAP expression in 
spinal cord.
4. Activation of spinal REV-ERBs ameliorated inflammatory and neuropathic 
pain.
5. Activation of spinal astrocytic REV-ERBs is crucial in antinociception.
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2Abstract
 The orphan nuclear receptors REV-ERBα and REV-ERBβ (REV-ERBs) are crucial in 
the regulation of inflammatory-related gene transcription in astroglioma cells, but their 
role in nociceptive transduction has yet to be elaborated. Spinal dorsal horn 
astrocytes contribute to the maintenance of chronic pain. Treatment of cultured spinal 
astrocytes with specific REV-ERBs agonists SR9009 or GSK4112 significantly 
prevented lipopolysaccharide (LPS)-induced mRNA upregulation of pronociceptive 
molecules interleukin-1β (IL-1β) mRNA, interleukin-6 (IL-6) mRNA and matrix 
metalloprotease-9 (MMP-9) mRNA, but not CCL2 mRNA expression. Treatment with 
SR9009 also blocked tumor necrosis factor-induced IL-1β mRNA, IL-6 mRNA and 
MMP-9 mRNA. In addition, treatment with SR9009 significantly blocked LPS-induced 
upregulation of IL-1β protein, IL-6 protein and MMP-9 activity. The inhibitory effects of 
SR9009 on LPS-induced expression of pronociceptive molecules were blocked by 
knockdown of REV-ERBs expression with short interference RNA, confirming that 
SR9009 exerts its effect through REV-ERBs. Intrathecal LPS treatment in male mice 
induces hind paw mechanical hypersensitivity, and upregulation of IL-1β mRNA, IL-6 
mRNA and glial fibrillary acidic protein (GFAP) expression in spinal dorsal horn. 
Intrathecal pretreatment of SR9009 prevented the onset of LPS-induced mechanical 
hypersensitivity, cytokine expression and GFAP expression. Intrathecal injection of 
3SR9009 also ameliorated mechanical hypersensitivity during the maintenance phase 
of complete Freund’s adjuvant-induced inflammatory pain and partial sciatic nerve 
ligation-, paclitaxel-, and streptozotocin-induced neuropathy in mice. The current 
findings suggest that spinal astrocytic REV-ERBs could be critical in the regulation of 
nociceptive transduction through downregulation of pronociceptive molecule 
expression. Thus, spinal REV-ERBs could be an effective therapeutic target in the 
treatment of chronic pain.
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5Introduction 
 There are an increasing number patients suffering from chronic pain, including 
neuropathic and inflammatory pain, which is associated with the growing population of 
elderly people (Ferreira and de Luca, 2017; Gagliese et al., 2017). In addition, for 
many of these patients, chronic pain is refractory to treatment with commonly used 
analgesics such as opioids and non-steroidal anti-inflammatory drugs. A number of 
studies have shown that dysregulation of the expression of a number of 
pronociceptive factors such as pro-inflammatory cytokines and chemokines in CNS 
glial cells contribute to the induction and maintenance of chronic pain (Grace et al., 
2014; Ji et al., 2016). While antagonists, neutralizing antibodies and synthesis 
blockers to pronociceptive molecules show varying degrees of efficacy in a range of 
chronic pain models, the analgesic effects of these reagents alone are not always 
robust. This suggests that targeting mechanisms that regulate the production of 
numerous molecules rather than targeting specific molecules may be crucial in 
alleviating chronic pain.
REV-ERBα and REV-ERBβ (REV-ERBs) are orphan nuclear receptors encoded by 
NR1D1 and NR1D2, respectively, which are expressed in various cell types (Kojetin 
and Burris, 2014). It has been demonstrated that REV-ERBs have crucial functions in 
the regulation of metabolism, inflammation and tumor growth (Sato et al., 2014; Solt et 
6al., 2012; Sulli et al., 2018). Like other nuclear receptors, REV-ERBs exert a ligand-
dependent inhibitory effect on gene transcription of various molecules (Kojetin and 
Burris, 2014; Yin and Lazar, 2005). Accumulating evidence has shown that REV-
ERBs negatively regulate the expression of various proinflammatory molecules such 
as the cytokine interleukin-6 (IL-6) and the chemokine CCL2, following binding of the 
synthetic REV-ERB-specific agonists GSK4112 and SR9009 in macrophages (Sato et 
al., 2014; Sitaula et al., 2015). A previous finding showed mildly increased mechanical 
nociceptive sensitivity in REV-ERBα knockout mice (Lee et al., 2016). Furthermore, it 
is possible that REV-ERBs might be a new target as analgesic for osteoarthritis-
induced pain (Das et al., 2018). However, the exact function and role of REV-ERBs in 
nociceptive transduction under chronic pain states has yet to be elaborated.
Over-activation of astrocytes in spinal dorsal horn contributes to the maintenance of 
chronic pain (Morioka et al., 2015; Zhuang et al., 2005). Production of pronociceptive 
molecules by spinal astrocytes could lead to persistent nociceptive hypersensitivity 
(Gao et al., 2009; Mika et al., 2013; Nakagawa and Kaneko, 2010). Intrathecal 
administration of fluorocitrate, an astrocytic inhibitor, ameliorated nociceptive 
hypersensitivity in chronic pain models (Shibata et al., 2011; Zhang et al., 2012b). 
These observations suggest that modulating spinal astrocytic activity, from an 
abnormal or pathophysiological state back to the normal, physiological state, could be 
7crucial in reducing or eliminating nociceptive hypersensitivity.
Stimulation of REV-ERBs expressed in C6 astroglioma cells suppressed cytokine 
tumor necrosis factor (TNF)-induced expression of both CCL2 and matrix 
metalloprotease-9 (MMP-9) (Morioka et al., 2016b). However, a role for REV-ERBs in 
regulating spinal astrocytic function and in nociceptive transduction in particular has 
yet to be elaborated. Thus, the current study examined the effects of synthetic REV-
ERBs specific agonists SR9009 and GSK4112 on REV-ERBs expressed on spinal 
astrocytes. The endotoxin lipopolysaccharide (LPS) elicits robust neuroinflammation 
in animal models and is widely used to induce inflammatory pain through activation of 
astrocytes in the CNS (Li et al., 2014; Lu et al., 2015). The current study examined the 
effect of REV-ERBs specific agonists on LPS-induced expression of pro-nociceptive 
molecules by spinal astrocytes and the antinociceptive effects of SR9009 on LPS-
induced mechanical hypersensitivity and inflammatory and neuropathic pain in mice.
8Materials and Methods
Animals
All experiments utilizing animals were conducted in accordance with the “Guidelines 
for the Care and Use of Laboratory Animals” established by The Japanese 
Pharmacological Society and Hiroshima University, and procedures were reviewed 
and approved by the Committee of Research Facilities for Laboratory Animal Science 
of Hiroshima University.
Pregnant Wistar rats (13 days) were obtained from Japan SLC, Inc. (Shizuoka, 
Japan) and 1-day old pups of both sexes were obtained from these rats. Male ddy 
mice, 6 weeks of age (Japan SLC, Inc.) were maintained in a vivarium, room 
temperature of 22±2℃, with a 12h light/dark cycle (lights on/off at 8:00 AM/8:00 PM), 
and given access to food and water available ad libitum during the experimental 
period. 
Reagents
 Lipopolysaccharide was obtained from Sigma Chemical Co. (St. Louis, MO, USA). 
SR9009, a REV-ERBs agonist (REV-ERBα EC50=0.67 μM, REV-ERBβ EC50=0.8 μM 
(Solt et al., 2012)), was obtained from Merck Millipore (Darmastadt, Germany). 
GSK4112 was purchased from Cayman Chemical (Ann Arbor, MI). GSK4112 is a 
9synthetic REV-ERBs agonist (The 50% effective concentration (EC50) to REV-ERBα is 
0.4 μM. The EC50 to REV-ERBβ is not known.) (Grant et al., 2010). RGFP966 is a 
selective histone deacetylase 3 (HDAC3) inhibitor (50% inhibitory concentration 
(IC50)=0.08 μM), and is reported to have no affinity to other types of HDAC (IC50>15 
μM). GSK4112, SR9009 and RGFP966 were dissolved in DMSO to a final 
concentration of 0.1% DMSO. Recombinant rat TNF was obtained from WAKO Pure 
Chemical Industries (Osaka, Japan). TNF was dissolved in distilled H2O. Paclitaxel 
was obtained from Sawai Pharmaceutical Co., Ltd. (Osaka, Japan).
Cell culture
The preparation of cultured spinal astrocytes has been described previously 
(Morioka et al., 2018). In brief, spinal cords isolated from neonatal Wistar rats were 
minced, and then incubated with trypsin and DNase Ⅰ . Dissociated cells were 
suspended in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal calf serum (FCS) and penicillin/streptomycin (100 units/ml and 100 μg/ml, 
respectively). Thereafter, cell suspensions were plated in 75cm2 tissue culture flasks 
(7.5-10×106 cells/flask) precoated with poly-L-lysine (10 μg/ml). Cells were 
maintained in a 10% CO2 incubator at 37℃. After 10 days, the flasks containing mixed 
glial cells were vigorously shaken and washed with PBS to remove microglial cells. 
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Remaining cells were trypsinized, and seeded to new flasks. After confluent state, 
cells were treated with 1 μM of cytosine β-D-arabinofuranoside (Sigma) to prevent 
proliferation of other cells such as microglia and fibroblasts for 2 days. Then, the 
flasks were again vigorously shaken and washed, and the cells were trypsinized. 
Thereafter, the remaining cells were transferred to 35-mm dishes (3-3.5×105 cells). 
After 3 days, the medium was replaced with DMEM without FCS and antibiotics. After 
an additional 24 hours of incubation, the cells were used in experiments. Greater than 
95% of the cells obtained using the current method expressed an astrocytic 
phenotype as confirmed by RT-PCR and Western blotting (Morioka et al., 2014).
Rat cultured spinal astrocytes have been shown to express Rev-erbα mRNA and 
Rev-erbβ mRNA (Morioka et al., 2016b). To induce expression of pro-nociceptive 
molecules, cells were incubated with either LPS (10 ng/ml) or TNF (10 ng/ml). The 
role of REV-ERBs in LPS-induced gene expression was assessed using 
pharmacological agents. Compounds that activated REV-ERB were incubated in 
astrocytes for 30 min followed by LPS or TNF incubation for up to 24 hours. Cell 
medium and cells were removed for assay at specific time points during LPS or TNF 
incubation (see Results).
Real-time PCR analysis
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cDNA synthesized using 1 μg of total RNA from cultured spinal astrocytes and mice 
spinal tissue were subjected to real-time PCR assay with specific primers and 
EXPRESS SYBR® GreenERTM qPCR SuperMix (Invitrogen, Carlsbad, CA, USA). The 
sequences of the primers are described in previous reports (Morioka et al., 2018; 
Zhang et al., 2016). Real-time PCR assays were conducted using a DNA engine 
Opticon 2 real-time PCR detection system (Bio-Rad, Hercules, CA, USA). The three-
step amplification protocol consisted of 3 min at 95℃ followed by 40 cycles of 95℃ 
for 15 s, 60℃  for 30 s, and 72℃  for 30 s. RNA quantification of target genes was 
calculated using the Ct method. The Ct values of each amplification were normalized 
to those obtained with the amplification of glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH).
Transfection of primary cultured astrocytes with small interfering RNA (siRNA)
 Forty-eight hours after the cells were seeded, the culture was replaced with Opti-
MEM medium (Invitrogen, Carlsbad, CA, USA), and then the cells were transfected 
with either siRNA, targeting rat Rev-erbα (siGENOME SMARTpool, Rat Nr1d1, GE 
Dharmacon, Lafayette, CO, USA), Rev-erbβ (siGENOME SMARTpool, Rat Nr1d2, 
GE Dharmacon) or non-targeting siRNA (siGENOME Non-Targeting siRNA Pool #2) 
by using Lipofectamine RNAi MAX reagent (Invitrogen). Twenty-four hours after 
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transfection, cells were treated with SR9009 for 30 min. Then, cells were further 
treated with LPS for 24 hours. 
ELISA
 Rat IL-1β, IL-6 and CCL2 protein levels in cell-conditioned medium were measured 
using ELISA kits (eBioscience, San Diego, CA, USA). After treatment with SR9009 for 
30 min, astrocytes were stimulated with LPS for 24 hours. Then, culture media were 
immediately collected and stored at -80℃ until assay. Each reaction was performed 
according to the manufacturer’s protocol.
Gelatin zymography
 To measure the activity of MMP-9, a gelatinase, gelatin zymography was performed 
based on methods described previously (Abe et al., 2016). In brief, after drug 
treatment, the culture supernatant of primary astrocytes was collected, and the 
supernatant was added to sample buffer (125 mM Tris-HCl, pH 6.8, 1% glycerol, 2% 
SDS, 0.01% bromophenol blue), and equal amount of protein were separated by 
electrophoresis using 8% SDS-polyacrylamide gel containing 0.1% gelatin under non-
reducing condition. After separation, gels were incubated with 2.5% Triton X-100 for 1 
hour, and further incubated with the buffer (50 mM Tris-HCl (pH 7.4, 10 mM CaCl2, 
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0.02% NaN3) for 20 hours at 37℃ . Then, gels were incubated with the staining 
solution (0.125% Coomassie Brilliant Blue R-250, 30% ethanol, 10% acetic acid) for 3 
hours, and destained in 25% methanol/7.5% acetic acid until bands showing 
gelatinolysis are clearly appeared. The density of specific band for MMP-9 was 
identified dependent on the molecular size (83 kDa) of MMP-9 described previous 
study (Abe et al., 2016) and using by the MMP Marker (PMC Cosmobio, Tokyo, 
Japan). The density was measured with Science Lab Image Gauge (Fuji Film, Tokyo, 
Japan).
Mouse intrathecal injection
 Intrathecal injections were performed on unanesthetized mice. In brief, mice were 
restrained with the left hand and the injection was performed with the right hand. The 
vertebral landmarks for L5 and L6 vertebrate were identified by palpation. An injection 
into the subarachnoid space between the L5 and the L6 vertebrae was done via a 27-
gage needle. Entry of the needle was confirmed with the presence of a tail flick. The 
injection volume of all other compounds was 5 μl. 
Inflammatory pain models
 Inflammation was induced by either intrathecal injection of LPS (0.1 μg/5 μl saline) or 
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subcutaneous injection of complete Freund’s adjuvant (CFA; 30 μl, 1mg of 
Mycobacterium tuberculosis/ml, Sigma) into the center of the plantar surface of left 
hind-paw in mice. The same volume of saline was used as a control.
Partial sciatic nerve ligation (PSNL)-induced neuropathic pain model 
 Under sodium pentobarbital (50 mg/kg, i.p.) anesthesia, a tight ligation of 
approximately one-third to one-half of the diameter of the left sciatic nerve (ipsilateral) 
was performed with 8-0 silk suture as described previously (Morioka et al., 2016a). In 
sham-operated mice, the sciatic nerve was exposed but not ligation. Previous studies 
have demonstrated that mechanical hypersensitivity was observed 3 days, and lasted 
at 3 weeks following PSNL (Morioka et al., 2015; Nakamura et al., 2015).
Paclitaxel-induced neuropathic pain model
Paclitaxel was dissolved in cremophor:ethanol (1:1) as the stock solution (6 mg/ml). 
This was diluted in saline to a final concentration of 0.2 mg/ml. The vehicle for 
paclitaxel was diluted with saline at the same proportion as the paclitaxel solution. 
Then, paclitaxel (2 mg/kg) was intraperitoneally administered in a volume of 0.1 
mL/20 g once per day for 5 times every other day (cumulative dose 10 mg/kg).
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Diabetes-induced neuropathic pain model
Diabetes was induced in mice fasted overnight by an injection of streptozotocin 
(Cayman Chemical). Streptozotocin was dissolved in saline immediately before 
injection and the solution administered intraperitoneally at a dose of 200 mg/kg. 
Control animals received a vehicle injection. Blood samples were collected from tail 
vein, and blood glucose levels were measured by a glucometer (Freestyle Freedom 
Lite; NIPRO, Osaka, Japan). Hyperglycemic mice (>300 mg/dl) at 21 days after 
streptozotocin injection were used for further analysis. 
Hind paw sensitivity to mechanical stimulation 
 All behavioral assessments were performed blinded. The withdrawal threshold (in 
grams) of the hind paw to mechanical stimulation was determined using von Frey 
filaments (Morioka et al., 2015). In brief, a von Frey filament was pressed against the 
mid-planter surface of the hind paw. The lowest force that caused responses such as 
lifting and licking of the hind paw was assigned as the withdrawal threshold. Each hind 
paw was tested three times, at 10 second intervals, and the mean withdrawal 
threshold was reported. Mice with inflammation, PSNL or paclitaxel that did not show 
robust mechanical hypersensitivity, hind paw withdrawal threshold >0.1 g, were 
excluded from the experiments. Prior to treatment, hind paw withdrawal thresholds 
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were 1.0±0.2 g (mean±SEM).
In LPS-treated mice, either 100 or 300 nmol of SR9009 or 100 nmol of GSK4112 
were intrathecally treated 1 hour before LPS injection. Withdrawal thresholds were 
measured 1, 2, 3, 6 and 24 hours following the second intrathecal injection. In CFA-
treated mice, 7 days following intraplantar treatment of CFA, mice received either an 
intrathecal treatment of 100 or 300 nmol of SR9009 or 100 nmol of GSK4112. 
Withdrawal thresholds were then measured 1, 2, 3, 6 and 24 hours post-injection. In 
PSNL mice, 14 days following surgery, mice received an intrathecal treatment of 100 
or 300 nmol of SR9009. Withdrawal thresholds were then measured 1, 2, 3, 4, 5 and 
24 hours post-injection. In paclitaxel mice, 14 days following the injection (6 days 
following the last injection), mice received an intrathecal treatment of 100 or 300 nmol 
of SR9009. Withdrawal thresholds were then measured 1, 2, 3, 6 and 24 hours post-
injection. In diabetic mice, 21 days following the injection of streptozotocin, mice 
received an intrathecal treatment of 100 or 300 nmol of SR9009. Withdrawal 
thresholds were then measured 1, 2, 3, 6 and 24 hours post-injection.
Immunohistochemistry
 Tissue sections of spinal dorsal horn from at least 3 mice of each treatment were 
used for immunohistochemistry. Thirty minutes after intrathecal administration of 
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SR9009, mice were further intrathecally injected of LPS. Fourteen days following 
PSNL, SR9009 was intrathecally injected. Then, after 3 hours, mice were 
anesthetized with isoflurane (induction; 5%, maintenance; 2-3%) and sodium 
pentobarbital (50 mg/kg, i.p.). Mice were transcardially perfused with 50 ml of saline 
followed by 100 ml of freshly prepared 4% (w/v) paraformaldehyde in 0.1 M 
phosphate buffer (pH = 7.4). The spinal tissues were quickly removed and postfixed in 
4% paraformaldehyde in 0.1 M phosphate buffer for three days at 4°C and then 
cryoprotected overnight in 30% (w/v) sucrose in 0.1 M phosphate buffer at 4°C. 
Tissues were embedded in Tissue-Tek OCT compound 4583 (Sakura Finetech, 
Tokyo, Japan) and frozen in liquid nitrogen, cut serially (20 μm thickness) in a 
cryostat, and collected onto glass slides. After slides were dried at room temperature, 
tissue sections were processed for double-labeling immunohistochemistry. Tissue 
sections were rinsed with phosphate-buffered saline, incubated in a blocking solution 
of 10% goat serum, 3% bovine serum albumin, 0.1% Triton X and 0.05% Tween-20 in 
phosphate-buffered saline for 2 hours at room temperature, and then incubated with 
rabbit anti-glial fibrillary acidic protein (GFAP) antibody (1:1,000, GTX72747, 
GeneTex Inc., Irvine, CA, USA). Tissues were incubated in primary antibodies for 72 
hours at 4°C, followed by corresponding secondary antibodies conjugated with Alexa 
Fluor® 488 (1:500) for 2 hours at 4°C in a dark chamber. The sections were then 
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extensively washed in phosphate-buffered saline and coverslipped. Sections were 
examined with a BZ-9000 Biorevo all-in-one fluorescence microscope (Keyence, 
Elmwood Park, NJ, USA). 
Statistical analysis
Data are expressed as the mean±SEM of at least three independent determinations. 
The effects of drug treatment on mRNA and protein levels were performed using a 
one-way analysis of variance (ANOVA) with a pairwise comparison by the Tukey-
Kramer method. Comparisons between two groups were performed using Student’s t-
test. Possible interactions between treatment over time on mechanical 
hypersensitivity were analyzed by two-way repeated-measures ANOVA, followed by 
the Tukey-Kramer method for post hoc comparisons. Differences were considered to 
be significant when the P value was less than 0.05.
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Results
REV-ERBs agonists block LPS-induced production of pronociceptive 
molecules in cultured spinal astrocytes
 Treatment of cultured spinal astrocytes with LPS markedly upregulated mRNA 
expression of pro-nociceptive molecules, including IL-1β, IL-6, MMP-9 and CCL2 (Fig. 
1a-1d). Induction of IL-β mRNA expression was observed 1 hour, peaked 6 hours and 
declined 24 hours after treatment with LPS (Fig. 1a). The inhibitory effect of a specific 
REV-ERBs agonist SR9009 on LPS-induced IL-β mRNA expression was observed 
beginning 1 hour after treatment with LPS, and this effect lasted over the 24 hours 
incubation period (Fig. 1a). Although LPS-induced IL-6 mRNA expression was also 
observed 1 hour after LPS incubation, induction of IL-6 mRNA was significantly 
prevented by pretreatment with SR9009 at 6 and 24 hours (Fig. 1b). MMP-9 mRNA 
expression was significantly induced 3 hours after LPS treatment, and inhibitory effect 
of SR9009 on the MMP-9 mRNA expression was also observed at the same time and 
this effect lasted 24 hours (Fig. 1c). Induction of CCL2 mRNA was observed 1 hour 
after LPS treatment--SR9009 had no effect on LPS-induced CCL2 mRNA expression 
(Fig. 1d). Incubation of cultured spinal astrocytes with 10 μM of SR9009 alone did not 
significantly affect mRNA expression of pronociceptive molecules (Fig. 1). 
Pretreatment with SR9009 (3, 5 and 10 μM) significantly suppressed the stimulatory 
20
effects of LPS on IL-1β mRNA, IL-6 mRNA and MMP-9 mRNA in a concentration-
dependent manner (Fig. 2a-2c). Although SR9009 slightly inhibited LPS-induced 
CCL2 mRNA expression, this effect was not statistically significant (Fig. 2d). 
Furthermore, pretreatment with 10 and 20 μM of GSK4112, also a REV-ERB agonist, 
significantly suppressed LPS-induced mRNA expression of IL-1β, IL-6, MMP-9, but 
not CCL2 (Fig. 3a-3d). Incubation of cultured spinal astrocytes with 20 μM of 
GSK4112 alone did not significantly affect mRNA expression of pronociceptive 
molecules (Fig. 3). In addition, pretreatment with SR9009 also significantly blocked 
TNF-induced mRNA expression of IL-1β, IL-6 and MMP-9 (Fig. 4a-4c). In TNF-treated 
cells, similar to that observed following LPS treatment, SR9009 showed a trend 
towards inhibition of CCL2 mRNA expression, which was not statistically significant 
(Fig. 4d). 
SR9009 inhibited LPS-induced protein expression of IL-1β, IL-6, CCL2 and MMP-9. 
Treatment with SR9009 (10 μM) significantly inhibited LPS-induced production of IL-
1β, IL-6, but not CCL2 (Fig. 5a-5c). Furthermore, gelatin zymography showed that 
stimulation with LPS increased the activity of MMP-9 released into the cultured 
medium, and this effect was significantly blocked by pretreatment with SR9009 (Fig. 
5d). Incubation of cultured spinal astrocytes with 10 μM of SR9009 alone did not 
significantly affect protein expression of pronociceptive molecules (Fig. 5a-5d).
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As mentioned earlier, cultured spinal astrocytes express both Rev-erbα mRNA and 
Rev-erbβ mRNA (Morioka et al., 2016b), and SR9009 acts on both types of REV-
ERBs with almost equal affinity (Solt et al., 2012). Thus, siRNA was used to inhibit 
expression of Rev-erbα mRNA and Rev-erbβ. As shown in Fig. 6a, the expression of 
both Rev-erbα mRNA and Rev-erbβ mRNA in cultured spinal astrocytes was 
significantly reduced after 48 hours of incubation with both siRNAs. Although 
significant inhibition by SR9009 on LPS-induced expression of IL-1β mRNA and 
MMP-9 mRNA was observed following knockdown of both Rev-erbs, the inhibitory 
effects of SR9009 were significantly reduced (Fig. 6b, 6d). Significant knockdown of 
both Rev-erbs mRNA almost completely reversed inhibitory effect of SR9009 on LPS-
induced IL-6 mRNA expression (Fig. 6c). Thus, these results demonstrate that 
stimulation of REV-ERBs prevent the expression of pro-nociceptive molecules in 
spinal astrocytes. 
Histone deacetylase 3 is a crucial mediator of the inhibitory effects of REV-
ERBs on LPS-induced mRNA upregulation of IL-1β and IL-6, but not MMP-9, in 
cultured spinal astrocytes
Previous studies have demonstrated that REV-ERBs repress gene transcription 
through recruitment of nuclear receptor corepressor 1 (NCoR1) and HDAC3. Thus, 
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astrocytes were pretreated with the HDAC3 inhibitor RGFP966. RGFP966 (2 μM) 
reversed the inhibitory effect of SR9009 on LPS-induced expression of IL-1β mRNA 
and IL-6 mRNA (Fig. 7a, 7b). However, pretreatment with RGFP966 did not reverse 
LPS-induced expression of MMP-9 mRNA (Fig. 7c). Treatment with RGFP966 alone, 
without LPS and SR9009, did not affect IL-1β, IL-6 and MMP-9 mRNA expression. 
These results indicate that HDAC3 is necessary in the inhibitory effect of REV-ERBs 
on inducing IL-1β and IL-6 transcription with LPS. However, in the case of LPS-
induced MMP-9 transcription, molecular mechanisms other than HDAC3 could be 
involved in the inhibitory effect of REV-ERB.
Stimulation of spinal REV-ERBs with specific agonists prevents LPS-induced 
mechanical hypersensitivity through downregulation of pronociceptive 
molecules 
 Potential antinociceptive effects of the activation of spinal REV-ERBs on LPS-
induced hind paw mechanical hypersensitivity were examined. Intrathecal treatment 
with LPS induced significant mechanical hypersensitivity beginning 1 hour after 
injection, and lasted for as long as 24 hours after injection (Fig. 8). Intrathecal 
pretreatment with either SR9009 (100 and 300 nmol) or GSK4112 (100 nmol) 
prevented the onset of LPS-induced mechanical hypersensitivity (Fig. 7a; LPS versus 
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LPS+SR9009 100 nmol; F1,144=15.3, P<0.001, interaction effect, F1,144=3.36, 
P=0.00669, LPS versus LPS+SR9009 300 nmol; F1,159=47.4, P<0.001, interaction 
effect, F1,159=6.00, P<0.001, LPS versus LPS+GSK4112 100 nmol; F1,127=14.5, 
P<0.001, interaction effect, F1,127=5.17, P<0.001). Treatment with SR9009 alone had 
no effect on withdrawal thresholds of saline-treated mice (Fig. 8).
The effect of SR9009 on the expression of IL-1β, IL-6 and MMP-9 in spinal dorsal 
horn of mice following intrathecal treatment with LPS was examined. As the current 
study showed that antinociception with SR9009 was at least observed between 2-6 
hours following administration of LPS, the effect of SR9009 on pronociceptive 
molecules expression was examined 3 hours after intrathecal treatment with LPS. The 
expression of both IL-1β and IL-6 mRNA was significantly increased in spinal dorsal 
horn following LPS treatment (Fig. 9a and 9b). Intrathecal pretreatment with SR9009 
(100 and 300 nmol) significantly reduced both IL-1β and IL-6 mRNA expression in 
mice spinal dorsal horn treated with LPS (Fig. 9a and 9b). Intrathecal pretreatment 
with SR9009 alone did not change either IL-1β or IL-6 mRNA expression (Fig. 9a and 
9b). In contrast to in vitro findings, intrathecal treatment with LPS did not significantly 
induce MMP-9 mRNA expression. Intrathecal SR9009 treatment in mice either with or 
without intrathecal LPS treatment did not affect MMP-9 mRNA expression (Fig. 9c).
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Intrathecal treatment with SR9009 prevents LPS-induced GFAP expression in 
spinal dorsal horn
 An increase of GFAP immunoreactivity, a cellular marker for astrocytes, was 
observed in the spinal dorsal horn 3 hours following intrathecal injection of LPS, 
indicating the presence of activated astrocytes. Intrathecal saline injection did not 
change GFAP expression. Mice were intrathecally pretreated with SR9009 (300 nmol) 
and 30 min later were intrathecally injected with LPS. SR9009 prevented LPS-induced 
GFAP expression in spinal dorsal horn (Fig. 10). The findings suggest that activation 
of REV-ERBs prevents astrocytic activation.
Effect of SR9009 on mechanical hypersensitivity in mouse models of 
inflammatory and neuropathic pain 
The effect of SR9009 on CFA-induced peripheral inflammatory pain was investigated 
(Fig. 11a). After 7 days, intraplantar injection of CFA significantly decreased 
withdrawal thresholds to mechanical stimuli, indicating mechanical hypersensitivity 
(Fig. 11a). Intrathecal treatment with SR9009 (300 nmol) significantly ameliorated 
CFA-induced mechanical hypersensitivity (CFA versus CFA+SR9009 300 nmol; 
F1,108=34.2, P<0.001, interaction effect, F1,108=4.03, P=0.00215). Antinociceptive 
effect of SR9009 was observed beginning 2 hours after injection, and sustained for at 
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least 3 hours after injection (Fig. 11a). Treatment of saline-treated mice with SR9009 
had no effect on withdrawal thresholds (Fig. 11a).
A potential antinociceptive effect of SR9009 on various types of neuropathic pain 
(PSNL, paclitaxel and streptozotocin) was examined. Fourteen days after surgery, 
intrathecal injection of SR9009 significantly reversed mechanical hypersensitivity in a 
dose-dependent manner in PSNL mice (Fig. 11b; PSNL versus PSNL+SR9009 100 
nmol; F1,155=42.5, P<0.001, interaction effect, F1,155=12.0, P<0.001, PSNL versus 
PSNL+SR9009 300 nmol; F1,151=74.3, P<0.001, interaction effect, F1,151=14.1, 
P<0.001). The antinociceptive effect of 300 nmol SR9009 was observed beginning 2 
hours after injection and sustained for at least 3 hours after injection. Intrathecal 
injection of SR9009 (100 nmol) also significantly increased withdrawal thresholds to 
mechanical stimuli for about 3 hours after injection in PSNL mice (Fig. 11b). 
Intrathecal treatment with SR9009 (300 nmol) in sham-operated mice had no effect on 
withdrawal thresholds (Fig. 11b). 
 Significant mechanical hypersensitivity was observed 14 days following the first 
injection of paclitaxel (Fig. 11c). Intrathecal treatment with SR9009 significantly 
ameliorated paclitaxel-induced mechanical hypersensitivity (Fig. 11c; paclitaxel 
versus paclitaxel+SR9009 100 nmol; F1,72=117.94, P<0.001, interaction effect, 
F1,72=9.00, P<0.001). The antinociceptive effect of 100 nmol SR9009 was significant 
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beginning 1 hour after injection and lasted for at least 6 hours after injection (Fig. 11c). 
By contrast, the antinociceptive effect of 300 nmol SR9009 was observed 2 hours 
after injection (Fig. 11c). Intrathecal injection of SR9009 (300 nmol) in vehicle-treated 
mice had no effect on withdrawal thresholds (Fig. 11c).
Significant mechanical hypersensitivity was observed three weeks following the 
injection of streptozotocin (Fig. 11d). Intrathecal treatment with 300 nmol of SR9009 
significantly ameliorated streptozotocin-induced mechanical hypersensitivity (Fig. 
11d; streptozotocin versus streptozotocin+SR9009 300 nmol; F1,66=82.9, P<0.001, 
interaction effect, F1,66=22.2, P<0.001). The antinociceptive effect of 300 nmol 
SR9009 was observed beginning 2 hours after injection, and lasted for at least 3 
hours after injection (Fig. 11d). By contrast, no antinociceptive effect was observed 
with 100 nmol SR9009 (Fig. 11d). Intrathecal injection of SR9009 (300 nmol) in 
vehicle-treated mice had no effect on withdrawal thresholds (Fig. 11d).
Intrathecal treatment with SR9009 reverses upregulation of GFAP in spinal 
dorsal horn following sciatic nerve injury
 Fourteen days following PSNL, during the period of significant mechanical 
hypersensitivity, spinal dorsal horn GFAP expression was significantly increased 
compared than that of sham mice (Fig. 12a and 12b). Treatment with SR9009 (300 
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nmol) significantly suppressed PSNL-induced GFAP expression in spinal dorsal horn 
(Fig. 12a and 12b). Treatment with vehicle or SR9009 alone had no effect on GFAP 
expression in spinal dorsal horn of sham mice (Fig. 12a and 12b).
28
Discussion
 The current study examined whether REV-ERBs could be targeted to relieve pain in 
various chronic pain states. In the current study, activation of cultured spinal 
astrocytes’ REV-ERBs prevented the expression of pronociceptive molecules by an 
inflammatory stimulus. During the maintenance phase of chronic pain, pronociceptive 
molecules produced by activated spinal astrocytes have a crucial role in mediating 
nociceptive hypersensitivity. In mice, activation of spinal REV-ERBs prevented LPS-
induced mechanical hypersensitivity through the downregulation of IL-1β and IL-6 
expression in spinal dorsal horn. Furthermore, activation of spinal REV-ERBs in mice 
reversed inflammatory and neuropathic mechanical hypersensitivity. In addition, 
stimulation of spinal REV-ERBs blocked upregulation of astrocytic activation marker 
protein GFAP in spinal dorsal horn of inflammatory and neuropathic pain model mice. 
Thus, the current findings suggest that astrocytic REV-ERBs could be crucial in the 
regulation of nociceptive transduction through the inhibition of the production of 
pronociceptive molecules.
 Significant involvement of REV-ERBs in the regulation of the response to 
inflammatory stimulation has been previously reported. Activation of REV-ERBs 
suppressed TNF-induced expression of CCL2 mRNA and MMP-9 mRNA, but not IL-6 
mRNA and inducible nitric oxide synthase mRNA, in C6 glioma cells (Morioka et al., 
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2016b). REV-ERBs appear to modulate the expression of proinflammatory molecules 
of various immune cells. Co-treatment with SR9009 blocked LPS and interferon-γ-
induced expression of IL-6 mRNA and IL-1β mRNA in mouse bone marrow-derived 
macrophages and activation REV-ERBα blocked IL-6 and CCL2 expression in mouse 
peritoneal macrophage (Sato et al., 2014; Sitaula et al., 2015). Mutation of REV-ERBs 
in bronchial epithelia augmented inflammatory responses and chemokine production, 
demonstrating the importance of activated REV-ERBs in the response to 
inflammatory stimuli (Pariollaud et al., 2018). Although Rev-erb mRNA expression has 
been observed in cultured spinal astrocytes (Morioka et al., 2016b), there are no 
reports regarding the function of REV-ERB subtypes in spinal astrocytes. 
The current study demonstrated that activation of REV-ERBs expressed on cultured 
spinal astrocytes suppressed LPS-induced expression of IL-1β, IL-6 and MMP-9. The 
proinflammatory cytokine TNF, which is mainly produced from activated microglia, 
has been shown to induce the production of pronociceptive molecules and evoke 
mechanical hypersensitivity, possibly through the activation of spinal astrocytes 
(Grace et al., 2014; Morioka et al., 2014). In the current study, activation of spinal 
astrocytic REV-ERBs also prevented TNF-induced expression of IL-1β, IL-6 and 
MMP-9. Thus, it is possible that REV-ERBs could suppress activation of astrocytes 
regardless of the inflammatory stimulus. REV-ERBs activation partially inhibited 
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induction of CCL2 expression, indicating that REV-ERBs play a minor role in the 
expression of this pronociceptive molecule and further suggests that REV-ERBs 
modulate the expression of many but not all pronociceptive molecules. The inhibitory 
effects of REV-ERBs agonist SR9009 can be attributed to direct stimulation of REV-
ERBs, as knockdown of both subtypes of REV-ERB by RNA interference led to a lack 
of efficacy of the agonist and SR9009 has no significant cross-activity against other 
members of the nuclear receptor superfamily (Solt et al., 2012). Together, these 
findings indicate that activation of spinal astrocytic REV-ERBs have a significant role 
in mediating antinociception. 
REV-ERBs bind to retinoic acid receptor-related orphan receptors (RORs) element 
(RORE) and compete in binding of positive transcriptional factor RORs (Kojetin and 
Burris, 2014; Sato et al., 2014). Furthermore, it has been shown that the HDAC3-
dependent transcriptional inhibition by REV-ERB activation could be mediated 
through the modulation of response elements different from that of the RORE motif 
(Zhang et al., 2015). These are the potential mechanism mediating REV-ERBs 
inhibition of transcription. The current study showed that HDAC3 activity is crucial in 
the inhibitory effects of REV-ERBs on LPS-induced expression of IL-1β and IL-6, but 
not MMP-9. Thus, it is possible that the effect of REV-ERBs on MMP-9 in spinal 
astrocytes could be regulated by a RORs-dependent mechanism. By contrast, a 
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previous study demonstrated that the inhibitory effect of REV-ERBs on MMP-9 
induction is dependent on HDAC3 in C6 glioma cells (Morioka et al., 2016b). Thus, 
these findings suggest that a REV-ERBs-mediated inhibitory mechanism could be 
dependent whether a ROR element or HDAC3-acting sites exist in the promoter 
regions of the target gene in different cell types. 
Activated spinal astrocytes have a key role in the maintenance of nociceptive 
hypersensitivity during the chronic pain state, so targeting astrocytic activity could 
lead to significant analgesia. While there are a number of mechanistic distinctions 
between inflammatory and neuropathic pain, it has been found that activation of spinal 
astrocytes is crucial across these models (Deng et al., 2017; Morioka et al., 2015; 
Qian et al., 2016). In the case of paclitaxel-induced neuropathy and PSNL, 
mechanical hypersensitivity appears to be mainly mediated through activation of 
spinal dorsal horn astrocytes and not microglia (Li et al., 2014; Morioka et al., 2015; 
Zhang et al., 2012a). Intrathecal LPS-induced mechanical hypersensitivity is likely 
due to activation of astrocytes in spinal dorsal horn (Lu et al., 2015; Saito et al., 2010; 
Zhao et al., 2014) and in the current study activation of REV-ERBs reduced both LPS- 
and PSNL-induced GFAP expression in spinal dorsal horn as well as suppressed 
mechanical hypersensitivity in both pain model mice. It is possible, then, that the 
antinociceptive effect of REV-ERBs activation observed across the current set of 
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chronic pain models could be mediated, in part, by suppression of astrocytic 
activation. 
While astrocytic functional status, such as GFAP immunoreactivity, was not directly 
assessed in the neuropathic and inflammatory pain models in the current study, 
reduced astrocytic functioning following REV-ERBs activation was inferred by 
reduced production of pronociceptive cytokines (Grace et al., 2014; Hansen and 
Malcangio, 2013; Nakagawa and Kaneko, 2010). The current study confirmed 
previous finding, in that stimulation of spinal dorsal horn astrocytes in vivo with LPS 
upregulated pronociceptive molecules, including IL-1β and IL-6, (Lu et al., 2015; Zhao 
et al., 2014). Previous studies also showed that these molecules mediate LPS-
induced hypersensitivity (Loram et al., 2011; Zhu et al., 2014). In the current study, 
upregulation of IL-1β and IL-6 was prevented and mechanical hypersensitivity was 
reduced with intrathecal treatment with a REV-ERB agonist. Thus, the decreased 
expression of pronociceptive molecules and decreased mechanical hypersensitivity 
observed following spinal REV-ERBs activation suggests decreased spinal astrocytic 
activation. 
The inhibitory role of REV-ERBα in gene expression is well known. REV-ERBβ 
contributes to the regulation of genes involved in lipid and energy homeostasis in 
skeletal muscle cells (Ramakrishnan et al., 2005). Furthermore, several types of 
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tumor cell predominantly express REV-ERBβ, and genetic or pharmacological 
inhibition of REV-ERBβ sensitizes cancer cells to the cytotoxic reagent chloroquine, 
which suppresses autophagy (De Mei et al., 2015). In the current study, the inhibitory 
role of each REV-ERB on the expression of pronociceptive molecules was not clearly 
demarcated. Preliminary findings suggested that although knockdown of both REV-
ERBs by RNA interference prevented SR9009-induced suppression of gene 
expression in cultured spinal astrocytes, knockdown of either REV-ERB alone did not 
(data not shown). Thus, each REV-ERB subtype could have a distinct function in 
regulating IL-6, IL-1β and MMP-9 transcription in spinal astrocytes.
A number of studies demonstrated that activation of REV-ERBs suppresses MMP-9 
expression in various cell types (Lam et al., 2013; Morioka et al., 2016b; Song et al., 
2018; Stujanna et al., 2017). Interestingly, in the current study, while in vitro astrocytic 
expression of MMP-9 mRNA increased following LPS treatment, spinal dorsal horn 
MMP-9 expression was not changed following intrathecal LPS treatment. Therefore, it 
is possible that MMP-9 might not be involved in LPS-induced nociceptive 
hypersensitivity in vivo. Alternatively, it is possible that MMP-9 is involved in late-stage 
maintenance of LPS-induced hypersensitivity, as the current study found peak in vitro 
expression of MMP-9 mRNA was later than that of IL-1β mRNA and IL-6 mRNA. In 
vivo findings in inflammatory and neuropathic pain models suggest that spinal MMP-9 
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is likely involved in late-stage maintenance of pain (Jiang et al., 2017; Kular et al., 
2012). Although further investigation is needed, downregulation of MMP-9 could be 
one of the mechanisms underlying the antinociceptive effect of SR9009 and MMP-9 
could be an important molecule mediating established nociceptive hypersensitivity 
across a variety of pain states.
While the current study confirms a role of spinal astrocytes in the maintenance of 
chronic pain, activated spinal microglial REV-ERBs could also have an 
antinociceptive function. Intrathecal injection of LPS activates both spinal dorsal horn 
microglia and astrocytes (Saito et al., 2010; Zhao et al., 2014; Zhu et al., 2014). 
Treatment of cultured mouse brain microglia with the REV-ERB agonist SR9011 
suppressed LPS-induced IL-6 expression (Nakazato et al., 2017). Therefore, it is 
possible that spinal microglial REV-ERBs could modulate spinal IL-1β and IL-6 mRNA 
expression in the current study, thereby contributing to REV-ERB agonist-mediated 
antinociception observed in the current study. However, whether spinal microglial 
REV-ERBs regulate the expression of proinflammatory molecules is not unknown. 
 In conclusion, the current findings demonstrated that stimulation of spinal astrocytic 
REV-ERBs suppressed astrocytic functioning, as inferred by decreased production of 
pronociceptive molecules IL-1β and IL-6. Stimulation of spinal astrocytic REV-ERBs 
could be effective in a wide range of pain states as astrocytes have a key role in 
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mediating chronic pain, regardless of etiology. Therefore, targeting spinal astrocytic 
REV-ERBs could be a novel therapeutic strategy for ameliorating chronic pain. 
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Figure Legends
Figure 1. Suppressive effect of SR9009 on LPS-induced upregulation of IL-1β mRNA 
(a), IL-6 mRNA (b), MMP-9 mRNA (c) and CCL2 mRNA (d) expression over time in 
cultured spinal astrocytes. After treatment with REV-ERB agonist SR9009 (10 μM) for 
30 min, cells were then stimulated with LPS (10 ng/ml) for time periods indicated (1, 3, 
6 and 24 hours). Then, expression levels of each mRNA were determined. Data are 
expressed as ratio of vehicle at each corresponding time point, and represent the 
mean± SEM for five independent experiments. *P<0.05, **P<0.01 vs. vehicle 
treatment. †P<0.05, ††P<0.01 vs. LPS treatment alone.
Figure 2. Effect of SR9009 on LPS-induced upregulation of IL-1β mRNA (a), IL-6 
mRNA (b), MMP-9 mRNA (c) and CCL2 mRNA (d) expression in cultured spinal 
astrocytes. After treatment with REV-ERB agonist SR9009 (3, 5 or 10 μM) for 30 min, 
cells were then stimulated with LPS (10 ng/ml) for 24 hours. Cells were also treated 
with SR9009 in the absence of LPS. Data represent the mean±SEM for six to nine 
independent experiments. **P<0.01 vs. vehicle treatment. ††P<0.01 vs. LPS treatment 
alone.
Figure 3. Effect of GSK4112 on LPS-induced upregulation of IL-1β mRNA (a), IL-6 
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mRNA (b), MMP-9 mRNA (c) and CCL2 mRNA (d) expression in cultured spinal 
astrocytes. After treatment with REV-ERB agonist GSK4112 (10 or 20 μM) for 30 min, 
cells were then stimulated with LPS (10 ng/ml) for 24 hours. Cells were also treated 
with GSK4112 in the absence of LPS. Data represent the mean± SEM for five 
independent experiments. **P<0.01 vs. vehicle treatment. †P<0.05, ††P<0.01 vs. LPS 
treatment alone.
Figure 4. Effect of SR9009 on TNF-induced upregulation of IL-1β mRNA (a), IL-6 
mRNA (b), MMP-9 mRNA (c) and CCL2 mRNA (d) expression in cultured spinal 
astrocytes. After treatment with SR9009 (3 or 5 μM) for 30 min, cells were then 
stimulated with TNF (10 ng/ml) for 24 hours. Cells were also treated with SR9009 in 
the absence of TNF. Data represent the mean± SEM for five independent 
experiments. **P<0.01 vs. vehicle treatment. †P<0.05, ††P<0.01 vs. LPS treatment 
alone.
Figure 5. Effects of SR9009 on LPS-induced upregulation of proinflammatory 
molecule protein expression in cultured spinal astrocytes. Effects of SR9009 on LPS-
induced expression of IL-1β (a), IL-6 (b) and CCL2 (c) protein in cultured spinal 
astrocytes. After treatment with SR9009 (10 μM) for 30 min, cells were then 
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stimulated with LPS (10 ng/ml) for 24 hours. The expression levels of these proteins 
were measured by ELISA. Data represent the mean± SEM for four independent 
experiments. *P<0.05, **P<0.01 vs. vehicle treatment. †P<0.05, ††P<0.01 vs. LPS 
treatment alone. (d) Effects of SR9009 on LPS-induced MMP-9 activity in cultured 
spinal astrocytes. After treatment with SR9009 (10 μM) for 30 min, cells were then 
stimulated with LPS (10 ng/ml) for 24 hours. The activity of MMP-9 was measured by 
zymography. The upper photograph is a representative zymography of MMP-9. 
Quantitative graph are shown below. Data represent the mean± SEM for six 
independent experiments. **P<0.01 vs. vehicle treatment. †P<0.05 vs. LPS treatment 
alone.
Figure 6. REV-ERB activation is involved in the suppressed expression of 
proinflammatory molecules in cultured spinal astrocytes. (a) Silencing of Rev-erbα 
and Rev-erbβ expression in cultured spinal astrocytes. Cells were transfected with 
either non-targeting siRNA or a combination of Rev-erbα- and Rev-erbβ-tageting 
silencing interfering RNA (Rev-erbα/β siRNA). After 24 hours, Rev-erb mRNA 
expression levels were examined. Data represent the mean± SEM for five 
independent experiments. **P<0.01 vs. non-targeting siRNA treatment. 
Downregulation of Rev-erbs expression by siRNA prevented the inhibitory effect of 
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SR9009 on LPS-induced upregulation of IL-1β mRNA (b), IL-6 mRNA (c) and MMP-9 
mRNA (d) expression in cultured spinal astrocytes. After transfection with either non-
targeting siRNA or a combination of Rev-erbα- and Rev-erbβ-targeting siRNA for 24 
hours, astrocytes were treated with 5 μM of SR9009 for 30 min. Cells were then 
treated with 10 ng/ml of LPS for 24 hours. Data represent the mean±SEM for five 
independent experiments. **P<0.01 vs. LPS alone at each siRNA treatment. †P<0.05, 
††P<0.01 vs. LPS + SR9009 at non-targeting siRNA.
Figure 7. HDAC3 is involved in REV-ERB-mediated inhibition of IL-1β mRNA and IL-6 
mRNA expression, but not MMP-9 mRNA expression. After treatment with the 
selective HDAC3 inhibitor RGFP966 (2 μM) for 30 min, cells were incubated with 
SR9009 (5 μM) for 30 min and then LPS (10 ng/ml) for 24 hours. Cells were also 
incubated in RGFP966 (2 μM) in the absence of SR9009 and LPS. Expression levels 
of L-1β mRNA (a), IL-6 mRNA (b) and MMP-9 mRNA (c) relative to LPS-treated 
astrocytes are shown. Data represent the mean±SEM for five to eight independent 
experiments. **P<0.01 vs. vehicle treatment. †P<0.05, ††P<0.01 vs. LPS treatment 
alone. ##P<0.01 vs. SR9009+LPS treatment.
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Figure 8. REV-ERBs agonists prevent mechanical hypersensitivity of mice 
intrathecally injected with LPS. One hour after intrathecal treatment with either 
SR9009 (100 or 300 nmol), GSK4112 (100 nmol) or DMSO, either LPS (0.1 μg) or 
saline was intrathecally injected and hind paw withdrawal thresholds were assessed 
over time. n=10-13/group. Data represent the mean±SEM. *P<0.05, **P<0.01 vs. 
saline-injected mice with DMSO at the corresponding time point. †P<0.05, ††P<0.01 
vs. LPS-injected mice with DMSO at the corresponding time point. 
Figure 9. Activation of REV-ERBs reduces expression of IL-1β mRNA and IL-6 mRNA 
in spinal dorsal horn of mice intrathecally injected with LPS. Thirty minutes after 
intrathecal treatment with either SR9009 (100 or 300 nmol) or DMSO, either LPS (0.1 
μg) or saline was intrathecally injected. Three hours later, spinal dorsal horn 
expression levels of L-1β mRNA (a), IL-6 mRNA (b) and MMP-9 mRNA (c) were 
measured. n=7-10/group. Data represent the mean± SEM. **P<0.01 vs. saline-
injected mice with DMSO. †P<0.05, ††P<0.01 vs. LPS-injected mice with DMSO.
Figure 10. Activation of REV-ERB prevents GFAP expression in spinal dorsal horn of 
mice intrathecally injected with LPS. (a) Thirty minutes after intrathecal treatment with 
either SR9009 (300 nmol) or DMSO, either LPS (0.1 μg) or saline was intrathecally 
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injected. Spinal dorsal horn was harvested 3 hours after LPS injection. Magnified 
photomicrographs of the white boxed areas are to the right. Scar bar=100 μm. (b) 
Quantitative analysis of expression of GFAP in spinal dorsal horn after injection of 
drugs described above at 3 hours following LPS injection. Data indicate mean ratio of 
sum of GFAP immunofluorescence intensity in each mice, and expressed as mean±
SEM for six to eight mice. **P<0.01 vs. saline-injected mice with DMSO. †P<0.05 vs. 
LPS-injected mice with DMSO.
Figure 11. Activation of REV-ERBs ameliorates mechanical hypersensitivity in mouse 
models of both inflammatory and neuropathic pain. a) Seven days after intraplantar 
treatment with either CFA or saline, either SR9009 (100 or 300 nmol) or DMSO was 
intrathecally injected and hind paw withdrawal thresholds were assessed over time. 
n=10/group. Data represent the mean±SEM. **P<0.01 vs. saline-injected mice with 
DMSO at the corresponding time point. ††P<0.01 vs. CFA-injected mice with DMSO at 
the corresponding time point. b) Fourteen days after sciatic nerve injury, either 
SR9009 (100 or 300 nmol) or DMSO was intrathecally injected and hind paw 
withdrawal thresholds were assessed over time. n=11-14/group. Data represent the 
mean±SEM. **P<0.01 vs. sham mice with vehicle at the corresponding time point. 
†P<0.05, ††P<0.01 vs. PSNL mice with vehicle at the corresponding time point. c) 
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Fourteen days after intraperitoneal treatment with either paclitaxel (PTX) or vehicle (6 
days after last injection), either SR9009 (100 or 300 nmol) or DMSO was intrathecally 
injected and hind paw withdrawal thresholds were assessed over time. n=5-8/group. 
Data represent the mean±SEM. *P<0.05, **P<0.01 vs. vehicle-injected mice with 
DMSO at the corresponding time point. †P<0.05, ††P<0.01 vs. PTX-injected mice with 
DMSO at the corresponding time point. d) Twenty one days after intraperitoneal 
treatment with either streptozotocin (STZ) or saline, either SR9009 (100 or 300 nmol) 
or DMSO was intrathecally injected and hind paw withdrawal thresholds were 
assessed over time. n=5-9/group. Data represent the mean± SEM. **P<0.01 vs. 
vehicle-injected mice with DMSO at the corresponding time point. ††P<0.01 vs. PTX-
injected mice with DMSO at the corresponding time point.
Figure 12. Activation of REV-ERB prevents GFAP expression in spinal dorsal horn of 
mice with PSNL. (a) Fourteen days after sciatic nerve injury, either SR9009 (300 
nmol) or DMSO was intrathecally injected. Spinal dorsal horn was harvested 3 hours 
after SR9009 injection. Magnified photomicrographs of the white boxed areas are to 
the right. Scar bar=100 μm. (b) Quantitative analysis of expression of GFAP in spinal 
dorsal horn after injection of drugs described above at 3 hours following SR9009 
injection. Data indicate mean ratio of sum of GFAP immunofluorescence intensity in 
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each mice, and expressed as mean±SEM for six to eight mice. *P<0.05 vs. saline-
injected mice with DMSO. †P<0.05 vs. LPS-injected mice with DMSO.
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